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The guideline for the management of hepatocellular carcino-
ma (HCC) was first developed in 2003 and revised in 2009 
by the Korean Liver Cancer Study Group and the National 
Cancer Center, Korea. Since then, many studies on HCC have 
been carried out in Korea and other countries. In particular, 
a substantial body of knowledge has been accumulated on 
diagnosis, staging, and treatment specific to Asian charac-
teristics, especially Koreans, prompting the proposal of new 
strategies. Accordingly, the new guideline presented herein 
was developed on the basis of recent evidence and expert 
opinions. The primary targets of this guideline are patients 
with suspicious or newly diagnosed HCC. This guideline pro-
vides recommendations for the initial treatment of patients 
with newly diagnosed HCC. (Gut Liver 2015;9:267-317)
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INTRODUCTION
1. Introduction
The guideline for the management of hepatocellular carci-
noma (HCC) was first developed in 2003 and revised in 2009 by 
the Korean Liver Cancer Study Group (KLCSG) and the National 
Cancer Center (NCC), Korea. Since then, many studies on HCC 
have been carried out in Korea and other countries. In particu-
lar, a substantial body of knowledge has been accumulated 
on diagnosis, staging, and treatment specific to Asian char-
acteristics, especially Koreans, prompting the proposal of new 
strategies. Accordingly, the new guideline presented herein was 
developed on the basis of recent evidence and expert opinions.
2. Target population
The primary targets of this guideline are patients with suspi-
cious or newly diagnosed HCC. This guideline provides recom-
mendations for the initial treatment of patients with newly diag-
nosed HCC. Moreover, this guideline includes some information 
about residual, progressed, and recurred tumors following initial 
treatment; however, it is not main topic of this guideline. Fur-
thermore, preemptive antiviral therapies for underlying chronic 
hepatitis, management of cancer pain, and assessment of tumor 
response are also included to facilitate the use of the guideline 
in clinical practice. 
3. Intended users
This revised guideline is intended to provide useful informa-
tion and guidance for all Korean clinicians in charge of the 
diagnosis and treatment of HCC. It also provides trainee doctors 
and teachers practical information on the management of HCC.
4. Developers and funding source
The KLCSG proposed revising the KLCSG-NCC Korea Practice 
Guideline, and the NCC, Korea agreed. The KLCSG-NCC Korea 
Practice Guideline Revision Committee (KPGRC), which included 
hepatologists, oncologists, surgeons, radiologists, and radiation 
oncologists, was subsequently formed (Appendix 1). All required 
funding was provided by the NCC, Korea. Each member of the 
HCC-KPGRC collected and evaluated relevant evidence, and 
wrote the manuscript. Conflicts of interests of the HCC-KPGRC 
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to: Korean Liver Cancer Study Group1 and National Cancer Center, Korea2
1101-3304 Brown Stone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 100-717, Korea 
    E-mail: liver@klcsg.or.kr 
2323 Ilsan-ro, Ilsan dong-gu, Goyang 410-769, Korea
   http://www.ncc.re.kr
Received on November 25, 2014. Accepted on March 9, 2015.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl14460
*Annotation: These guidelines are organized opinions for which special-
ists reviewed current medical literature so that they may actually be 
used as references for clinical practice, research, and education about 
hepatocellular carcinoma. These guidelines are intended to be flexible 
in contrast to ”standards of care,” which are mandatory policies to be 
followed in every case. These guidelines were prepared by a joint col-
laboration of the Korean Liver Cancer Study Group (KLCSG) and the 
National Cancer Center (NCC), Korea. This may not be revised, changed, 
or assumed without prior consent from these two institutions.
268  Gut and Liver, Vol. 9, No. 3, May 2015
members are summarized in Appendix 2.
5. Evidence collection
The HCC-KPGRC collected and evaluated the literature rel-
evant to HCC management by searching in using MEDLINE (up 
to 2014) for updated revisions. Only English and Korean litera-
ture was searched. The search term “hepatocellular carcinoma” 
and other keywords related to clinical questions shown were 
used (Appendix 3); these clinical questions contained a wide 
range of key topics including epidemiology, prevention, diagno-
sis, staging, treatment, and assessment of tumor response. 
6. Levels of evidence and grades of recommendation
Relevant literature was systematically reviewed. The evidence 
and recommendations were graded according to the Grading 
of Recommendations, Assessment, Development, and Evalua-
tion (GRADE) system with minor modifications.1-4 The levels of 
evidence were assessed on the basis of the possibility of changes 
in the estimate of clinical impact by further research, and were 
categorized as high (A), moderate (B), or low (C). For example, 
A-level evidence is similar but not identical to that from one 
or more randomized controlled trials. If there is only a slight 
possibility of the level of evidence changing, because further 
randomized controlled trials are unlikely to be conducted, such 
evidence could be considered level A. According to the GRADE 
system, the grades of recommendation were classified as strong 
(1) or weak (2), collectively considering the level of evidence, 
quality, patient-centered outcomes, and socioeconomic aspects 
of each study. Therefore, each recommendation was graded on 
the basis of the level of evidence (A–C) and grades of recom-
mendation (1 or 2) as follows: A1, A2, B1, B2, C1, or C2 (Table 1). 
This guideline avoided giving C2 grades.
7. List of clinical questions
The committee considered the following questions from four 
departments as key factors to be addressed in this guideline 
(Appendix 3). The committee reviewed the evidence and sug-
gested recommendations through intra- and interdepartmental 
discussion.
8. Manuscript review
Drafts of the revised guideline were thoroughly reviewed at 
several intradepartmental, three interdepartmental, and four 
departmental head meetings. In addition to the contents, meth-
odological validity was evaluated on the basis of the Appraisal 
of Guidelines for Research and Evaluation II (AGREE II) instru-
ment.5,6 A revised draft of the manuscript was reviewed at an 
external review board meeting and an open symposium, and 
was modified further before publication. The external review 
board comprised eight specialists who are or were the head of 
the KLCSG or the Korean Association for the Study of the Liver 
(KASL). The final manuscript was endorsed by the board of ex-
ecutives of the KLCSG and the NCC, Korea.
9. Guideline release
The revised HCC guideline was presented at Liver Week 2014 
(the Korean Association for the Study of the Liver-KLCSG-Kore-
an Association of Hepato-biliary and Pancreas Surgery-Korean 
Liver Transplantation Society meeting) on June 14, 2014. The 
Korean edition is available at http://www.klcsg.or.kr or http://
ncc.re.kr.
10. Plan for updates
Updates will be planned when new major evidence regarding 
the diagnosis and/or treatment of HCC is accumulated. 
EPIDEMIOLOGY
According to the central cancer registration statistics pub-
lished in 2013, there were 218,017 cases of cancer in Korea in 
2011. Among them, 7.6% (16,434) of all malignancies were 
primary liver cancer cases, ranking fifth in incidence.7 Regard-
ing sex, 12,189 cases were in men and 4,274 cases were in 
women, making primary liver cancer the fourth and sixth most 
Table 1. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)
Quality of evidence Criteria
High (A) Further research is unlikely to change confidence in the estimate of the clinical effect.
Moderate (B) Further research may change confidence in the estimate of the clinical effect.
Low (C) Further research is very likely to impact confidence on the estimate of clinical effect.
Strength of recommendation Criteria
Strong (1) Factors influencing the strength of the recommendation included the quality of the evidence, presumed  
  patient-important outcomes, and cost.
Weak (2) Variability in preferences and values, or more uncertainty; recommendation is made with less certainty, 
  higher cost or resource consumption.
Among the quality levels of evidence originally included in the GRADE system, we excluded “very low quality” (D) (i.e., the estimate of the effect 
is very uncertain) from this guideline for convenience.
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common cancer in men and women in Korea, respectively; the 
male:female ratio was 2.85:1.7 Regarding age, primary liver 
cancer occurred most frequently in patients in their 50s (28.6%) 
followed by 60s (26.0%) and 70s (22.3%).7 The crude incidence 
rate, i.e., the number of newly occurring cancer patients during 
the observation period among the study population, was 32.9 
(male, 48.6; female, 17.1) per 100,000 population. According to 
an annual report of the 2010 cancer registration statistics, the 
diagnostic code of HCC accounted for approximately 76.0% 
among all primary liver cancers. According to the age-stan-
dardized incidence rate, compensated with the mid-year popula-
tion in 2000, the incidences of primary liver cancer occurrence 
were 28.9 (male, 48.5; female, 12.6) per 100,000 population in 
1999 and 22.8 (male, 36.7; female, 10.5) in 2011. This implies 
that the occurrence of primary liver cancer has decreased some-
what, showing an annual rate of change of –1.8%. However, 
the number of new cases of primary liver cancer in 1999 was 
13,286 (male, 10,027; female, 3,259), and the sex ratio was 
similar to that of recent data, whereas the total number of cases 
is less than that of the recent data (Fig. 1).7,8 This may reflect the 
age structure of the Korean population, as the absolute number 
of liver cancer cases is increasing, whereas the age-standardized 
incidence is decreasing.9
Regarding regional distribution, in 1999, of HCC occurrence 
in Jeonnam, Gyeongbuk, and Gyeongnam was 28.9, 26.8, and 
26.4 per 100,000 population, respectively. The occurrence of 
HCC was the lowest in Daejeon at 14.8 per 100,000 population; 
those in Gyeonggi and Seoul were 18.2 and 18.7 per 100,000 
population, respectively. In 2010, the regional incidences of 
HCC in Jeonnam, Jeju, Busan, Gyeongnam, Gyeongbuk, and 
Gangwon were 23.8, 20.8, 20.7, 20.4, 20.1, and 19 per 100,000 
population, respectively. Regions of relative low incidence were 
Jeonbuk, Chungnam, Chungbuk, with 14.9, 15.1, and 15.6, re-
spectively, as well as Seoul, Daegu, and Daejeon, each with 15.9 
per 100,000 population.8,9
In 2011, the national primary liver cancer prevalence was 
47,697 (age-standardized prevalence, 67.1 per 100,000 popula-
tion), ranking sixth after thyroid, stomach, colon, breast, and 
lung cancers. Regarding the sex-specific prevalence, primary 
liver cancer was ranked at fourth in men (prevalence, 35,689; 
age-standardized prevalence, 107.2/100,000) and ninth in 
women (prevalence, 12,009; age-standardized prevalence, 
31.3/100,000); the male:female prevalence ratio was 2.97:1. Re-
garding 5-year prevalence, the age-standardized prevalence of 
primary liver cancer increased: 43.0 in 2007, 45.1 in 2008, 46.1 
in 2009, 46.6 in 2010, and 47.9 per 100,000 population in 2011, 
respectively.7,8 The reason for the increasing prevalence of pri-
mary liver cancer despite its decreasing incidence is presumably 
because the survival rate of liver cancer patients is increasing.9
Liver cancer is the main cause of death of Korean men in 
their 50s. According to the National Statistics Office of Korea, 
22.5 people (male, 33.7; female, 11.3) per 100,000 population 
die annually from liver cancer. While the most frequent cause of 
death in people after the age of 40 is malignancy, liver cancer is 
the top-ranked cause of death in people in their 40s and 50s.10 
According to a recent report of 10 principal cancers, shows that 
the 5-year cancer relative survival rates for liver cancer were 
10.7%, 13.2%, 20.2%, 27.3%, and 28.6% from 1993–1995, 
1996–2000, 2001–2005, 2006–2010, and 2007–2011, respec-
tively, showing consistent improvement (Fig. 2). However, the 
prognosis of liver cancer remains very poor compared to the 
66.3% 5-year relative survival rates of all cancer patients from 
2007 to 2011 in Korea.7,8 The prognosis of HCC is closely related 
to liver function. A report from Europe stated that a few patients 
excluded from curative treatment study (i.e., liver resection, 
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Fig. 1. Annual cases and incidence rate of hepatocellular carcinoma.8
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Fig. 2. Changes in the 5-year survival rates of overall cancers and 
hepatocellular carcinoma (HCC).8
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liver transplantation [LT], and percutaneous ethanol injection) 
showed a 3-year survival rate of 28% without any treatment for 
HCC.11 However, this could be considered to be a result of selec-
tion bias. In Korea, according to the 2003–2005 randomized 
registration of HCC (n=4,521), modified Union for International 
Cancer Control (mUICC) stages I, II, III, IVa, and IVb were 10.7%, 
33.4%, 27.7%, 10.3%, and 7.9%, respectively; the 3-/5-year 
survival rates in these stages were 62.3%/52.0%, 48.1%/36.0%, 
22.3%/15.5%, 8.0%/6.5%, and 8.0%/6.1%, respectively.12 A re-
cent single-center cohort study reports that 8.9%, 29.6%, 24.8%, 
23.1%, and 13.6% of 1,972 patients with HCC from 2004 to 
2009 were mUICC stage I, II, III, IVa, and IVb, respectively.13 The 
5-year survival rates in stages I, II, III, IVa, and IVb were 71.1%, 
59.8%, 25.0%, 4.6%, and 2.1%, respectively, showing improve-
ment in overall survival rates compared with the previous 
2000–2003 cohort study. Improved survival rates in hepatitis 
B-related advanced HCC highlights the importance of antiviral 
therapy for hepatitis B-positive patients.13 The risk factors for 
HCC are relatively well known14,15 and include chronic hepatitis 
B/C, liver cirrhosis, alcoholic liver disease, obesity- and fatty 
liver disease-related diabetes mellitus,15,16 and aflatoxin.17 In Ko-
rea, one study reports that the underlying liver diseases of HCC 
patients included hepatitis B (72.3%), hepatitis C (11.6%), alco-
holic liver disease in (10.4%), and non-B non-C hepatitis (0.7%).12 
Another study reports that 74.6% of HCC patients were positive 
for hepatitis B virus (HBV), 9.3% were positive for hepatitis C 
virus (HCV), 7.4% were long-term alcohol abusers, and 8.7% 
had unidentified causes (probably metabolic liver disease).13 HCC 
develops in 1%–4% of cirrhotic patients annually18 and eventu-
ally develops in approximately one-third of cirrhotic patients.19 
In Korea, the number of carriers of hepatitis B decreased mark-
edly because of hepatitis B vaccination and prevention services 
in vertical transmission. Although antiviral therapy for chronic 
hepatitis B and C is expected to further decrease the incidence 
of HCC, metabolic liver disease may increase as a cause of HCC 
in the future.
PREVENTION
The primary, secondary, and tertiary prevention of HCC de-
velopment are defined as follows. Primary prevention of HCC 
can be achieved by universal vaccination against HBV infec-
tion,20 encouragement of healthy lifestyles preventing obesity 
and alcohol abuse, and controlling metabolic conditions. Sec-
ondary prevention is the prevention of HCC development in 
patients with chronic viral hepatitis through histologic improve-
ment of inflammation and fibrosis by sustained suppression 
or eradication of hepatitis virus. Finally, tertiary prevention 
involves means to prevent recurrence in HCC patients after cu-
rative treatment.
The World Health Organization recommends vaccination 
against HBV for all newborns and high-risk groups.21 As peri-
natal or early postnatal transmission is an important cause of 
chronic HBV infection worldwide, the first dose of hepatitis B 
vaccine should be administered as soon as possible after birth. 
Vaccination is also recommended for age-specific cohorts (i.e., 
young adolescents) and people with risk factors for acquiring 
HBV infection, including healthcare workers, travelers to areas 
where HBV-infection is prevalent, intravenous drug users, peo-
ple with multiple sex partners, and adult patients who do not 
have hepatitis B surface antigen or surface antibody. However, 
there is currently no vaccination against HCV.
Antiviral therapies leading to sustained suppression of viral 
replication in chronic hepatitis B patients and inducing sus-
tained virologic response in chronic hepatitis C patients are 
recommended because they prevent progression to cirrhosis and 
the development of HCC. Antiviral therapies should be admin-
istered according to the KASL guidelines for the management 
of chronic hepatitis B and C infections.22 Interferon and oral 
nucleos(t)ide analogues are now available for HBV treatment. 
Observational studies assessing the effect of interferon show a 
potential effect in the reduction of HCC incidence.23 Similarly, 
a randomized controlled trial assessing the effect of lamivudine 
shows a significant reduction in HCC incidence (32 months of 
follow-up; lamivudine vs placebo, 3.9% vs 7.4%; p=0.047).24 
Although HCC reduction after antiviral treatment remains con-
troversial,25 a recent study shows significant reduction in HCC 
incidence in patients treated with entecavir (5 years of follow-
up; entecavir vs control, 3.7% vs 13.7%; p<0.001).26
In chronic hepatitis C patients, whether interferon treatment 
reduces HCC risk (favors reducing; treated vs control, 4% vs 
38%; p=0.002) is controversial.27 However, others reported no 
significant difference in HCC incidence between treated and 
untreated controls.28 The results of a meta-analysis of 4,700 
patients from 20 studies suggested the risk of HCC is reduced 
among interferon-treated patients (relative risk [RR], 0.43; 95% 
confidence interval [CI], 0.33 to 0.56).29 Furthermore, the risk 
of HCC is reduced among patients with HCV who achieve a 
sustained virological response with antiviral therapy compared 
with nonsustained virological response (RR, 0.35; 95% CI, 0.26 
to 0.46). However, once cirrhosis is established, there is no 
conclusive evidence that antiviral therapy can prevent or delay 
the occurrence of HCC. Previous studies including Hepatitis C 
Antiviral Long-term Treatment against Cirrhosis (HALT-C)30,31 
and Evaluation of PegIntron in Control of Hepatitis C Cirrhosis 
(EPIC) studies32 show that maintenance therapy with pegylated-
interferon in cirrhotic patients does not significantly decrease 
the incidence of HCC; the study populations included in these 
trials were patients with nonresponse to prior interferon treat-
ment. Therefore, additional studies are required to determine the 
potential preventive effect of monotherapy or combinations of 
new direct-acting antivirals with interferon in cirrhotic patients.
Regarding tertiary prevention for HCC, there is no conclusive 
evidence that antiviral therapy can prevent or delay HCC recur-
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rence after curative treatment. Yin et al.33 reported oral antiviral 
treatment against HBV significantly decreased HCC recurrence 
and HCC-related death after resection, with hazard ratios (HRs) 
of 0.48 (95% CI, 0.32 to 0.70) and 0.26 (95% CI, 0.14 to 0.50), 
respectively. In a study by Chen et al.34 that enrolled 268 pa-
tients (133 in the interferon a-2b arm), the median recurrence-
free survival in the interferon a-2b and control arms were 
42.2 (95% CI, 28.1 to 87.1) and 48.6 (95% CI, 25.5 to infinity) 
months, respectively (p=0.828). A meta-analysis including 551 
patients from nine cohorts35 shows a significant difference in 
the incidence of HCC recurrence in favor of the antiviral treat-
ment group (55% vs 58%; odds ratio [OR], 0.59; p=0.04) after 
curative treatment of HBV related-HCC; the risk of HCC was 
reduced by 41% in the antiviral treatment group. There were 
also significant differences in favor of the antiviral treatment 
group with respect to liver-related mortality (0% vs 8%; OR, 0.13; 
p=0.02) and overall mortality (38% vs 42%; OR, 0.27; p<0.001). 
Miao et al.36 performed a meta-analysis of the impact of postop-
erative antiviral treatment on tumor recurrence and survival of 
patients with chronic HBV or HCV infection-related HCC after 
curative therapy; 1,224 patients were included in their analysis. 
The estimated ORs for the 1-, 3-, and 5-year recurrence in HBV-
related HCC were 0.59, 0.43, and 0.21, respectively.
In HCV-related HCC patients, Shiratori et al.37 report that the 
rates of second or third recurrence appeared to be lower in the 
interferon group than the untreated group. The 5- and 7-year 
survival rates of patients treated with interferon were of 68% 
and 53%, respectively; those of untreated patients were 48% 
and 23%, respectively. Mazzaferro et al.38 recently reported that 
while no treatment effect was apparent on early recurrence in 
HCV-positive patients, there was a significant benefit on late 
recurrence (HR, 0.3; p=0.04). According to Miao et al.,36 the esti-
mated ORs for the 1-, 3-, and 5-year recurrence in HCV-related 
HCC were significantly reduced to 0.52, 0.23, and 0.37, respec-
tively. 
In addition to HBV-, HCV-, and alcohol-related chronic liver 
disease, associations between diabetes and obesity, with HCC 
were recently reported.39,40 Policies for preventing HCV/HBV 
transmission encourage lifestyles that prevent obesity and al-
cohol abuse as well as the control of metabolic conditions such 
as diabetes. Bravi et al.41 reported that coffee consumption re-
duced the RR of HCC compared to no coffee consumption: the 
summary RR was 0.72 for low consumption and 0.44 for high 
consumption. Their meta-analysis indicates the risk of HCC is 
reduced by 40% for any coffee consumption versus no con-
sumption.
Recommendations (Table 2)
1. Hepatitis B vaccination is recommended for all newborns 
(A1) and high-risk individuals (i.e., HBsAg-negative and anti-
HBs-negative) (B1).
2. General preventive measures include the followings: pre-
vention of HBV/HCV transmission (A1), avoidance of alcohol 
abuse, and control of metabolic disorders such as obesity and 
diabetes (C1).
3. Antiviral therapy as secondary prevention against HCC 
should follow the KASL guidelines for the management of 
chronic hepatitis B/C (A1).
4. Antiviral therapy should be considered after curative treat-
ment for chronic viral hepatitis-related HCC to reduce the risk 
of recurrence (B1).
DIAGNOSIS
The diagnosis of HCC is based on pathology or noninvasive 
criteria in high-risk groups. However, noninvasive criteria for 
HCC diagnosis vary greatly among guidelines. Most patients 
with HCC have definite risk factors such as HBV infection, HCV 
infection, and cirrhosis. Regular surveillance (i.e., abdominal 
ultrasound and serum a-fetoprotein [AFP]) is warranted in 
these high-risk groups.42,43 The cost-effectiveness and survival 
benefit of patients with early HCC detected in surveillance 
programs have been documented in previous studies.44 Dy-
namic contrast-enhanced computed tomography (CT), dynamic 
contrast-enhanced magnetic resonance imaging (MRI), or MRI 
using hepatocyte-specific contrast agent (i.e., gadolinium eth-
oxybenzyl diethylenetriamine pentaacetic acid [Gd-EOB-DTPA]) 
are preferentially recommended if HCC is suspected in a surveil-
lance program.
Serum AFP has been traditionally and widely used as a tumor 
marker of HCC. However, serum AFP level is normal in up to 
35% of cases of small HCC and can be nonspecifically elevated 
in patients with active hepatitis or active hepatocyte regenera-
tion. Although the glycosylated AFP/total AFP ratio (AFP-L3), 
des-γ-carboxy prothrombin or protein induced by vitamin K 
absence-II (PIVKA-II) have been suggested as new tumor mark-
ers for the diagnosis of HCC, none have demonstrated a definite 
role in the diagnosis of HCC. A recent Japanese guideline in-
dicates the combined use of tumor markers (AFP >200 ng/mL, 
AFP-L3 >15%, or PIVKA-II >40 mAU/mL) for the diagnosis of 
HCC.45 Several Korean retrospective studies also reported the 
clinical usefulness of these new tumor markers.46,47 However, 
further well-designed studies are warranted to confirm their 
roles in the diagnosis of HCC. If serum AFP level increases 
steadily over time, especially in hepatitis B patients with fully 
suppressed viral activity, the development of HCC should be 
suspected, and a detailed imaging study is strongly recommend-
ed.45,48,49
As the noninvasive diagnosis of HCC mostly depends on im-
aging studies, the sensitivity and specificity of imaging modali-
ties are important for accurate diagnosis. Studies investigating 
the roles of imaging techniques in patients undergoing LT report 
that the diagnostic sensitivity of dynamic CT is 75.0%, while 
those of dynamic MRI are 100% for HCC ≥2 cm in diameter 
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Table 2. Summary of the Recommendations of the 2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Topic Recommendation
Prevention 1. Hepatitis B vaccination is recommended for all newborns (A1) and for high-risk individuals (HBsAg-negative and 
anti-HBs-negative) (B1).
2. General preventive measures include the followings: prevention of HBV/HCV transmission (A1), avoidance of alco-
hol abuse, and control of metabolic disorders such as obesity and diabetes (C1).
3. Antiviral therapy as secondary prevention of HCC should follow the KASL guidelines for the management of chron-
ic hepatitis B/C (A1).
4. Antiviral therapy should be considered after curative treatment for chronic viral hepatitis-related HCC in order to 
reduce the risk of recurrence (B1).
Diagnosis 1. HCC is diagnosed on the basis of either pathology or clinical criteria in case of the high-risk group (HBV/HCV posi-
tive or cirrhosis) (A1).
2. When HCC is suspected during surveillance in the high-risk group, dynamic contrast-enhanced CT/MRI or liver-
specific contrast-enhanced MRI should be performed for diagnosis (B1).
3. In the high-risk group, HCC can be diagnosed for nodules ≥1 cm in diameter if one or two of the abovementioned 
imaging techniques show typical features of HCC (for the diagnosis of nodules 1–2 cm in diameter, two or more 
imaging modalities are required if a suboptimal imaging technique is used). Typical features of HCC include arterial 
phase enhancement with washout in the portal or delayed phase (B1).
4. Nodules <1 cm in diameter can be diagnosed as HCC in high-risk patients when all of the following conditions are 
met: typical features of HCC in two or more of the abovementioned imaging modalities and continuously rising se-
rum a-fetoprotein with hepatitis activity under control (C1).
5. Pathological diagnosis should be considered when the clinical criteria are not met or typical features of HCC are not 
present. The presence of indeterminate nodules despite imaging workup or pathologic examination needs to be fol-
lowed up with repeated imaging and serum tumor marker analysis (B1).
6. Limitation of radiation exposure in diagnosis and staging is not considered relevant in patients with HCC. CT is es-
sential for diagnosis and follow-up in HCC patients (C1).
Staging 1. This guideline adopts the modified Union for International Cancer Control stages as a primary staging system, with 
the Barcelona Clinic Liver Cancer staging system serving as a complementary system (B1).
Surgical resection 1. Surgical resection is the first-line treatment for patients with intrahepatic single-nodular HCC and well-preserved 
liver function classified as Child-Pugh class A, without portal hypertension or hyperbilirubinemia (A1).
2. Limited resection can be selectively applied to HCC patients with liver function of Child-Pugh class A or superb B 
and with mild portal hypertension or mild hyperbilirubinemia (C1).
3. HCC resection can be considered in patients with three or fewer intrahepatic tumors without macrovascular inva-
sion, if hepatic function is well preserved (C2).
4. Laparoscopy-assisted resection can be considered for HCC located in the lateral section of the left lobe or in the an-
terolateral segment of the right lobe (B2).
Transplantation 1. Deceased donor liver transplantation is the first-line treatment for patients with single-nodular HCC <5 cm in diam-
eter or three or fewer nodules ≤3 cm in diameter (Milan criteria), which are not indicated for resection (A1).
2. Locoregional therapies (local ablation or TACE) are recommended if the timing of transplantation is not predictable 
(B1).
3. Downstaging (e.g., with TACE) can be considered for HCCs exceeding the criteria for transplantation (C2).
4. Living donor liver transplantation is an effective alternative to deceased donor transplantation (B1).
5. An expanded indication for transplantation beyond the Milan criteria can be considered in HCC cases without de-
finitive vascular invasion or extrahepatic spread if other effective treatment options are inapplicable (C2).
6. Salvage transplantation can be indicated for recurrent HCC after resection according to the same criteria as for first-
line transplantation (B1).
Local ablation 1. RFA provides survival comparable to that of resection in patients with single-nodular HCCs ≤3 cm in diameter (A2).
2. RFA is superior to PEIT in terms of anticancer effect and survival (A1). For HCCs ≤2 cm in diameter, PEIT can be 
considered if RFA is unfeasible, because the outcomes of both modalities are similar (A2). 
3. Survival outcome can be improved by combining TACE and RFA compared to RFA alone in patients with tumors 3–5 
cm in diameter if resection is unfeasible (A2).
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but only 52% for HCC <2 cm in diameter.50-52 The overall sen-
sitivities of ultrasound, dynamic CT, and dynamic MRI for the 
noninvasive diagnosis of HCC are 61%–67%, 68%–91%, and 
81%–100%, respectively.53-55 
If liver nodules are found during surveillance in high-risk 
groups, dynamic CT, dynamic MRI, or MRI using hepatocyte-
specific contrast agent should be performed. If the typical hall-
mark of HCC (i.e., hypervascularity in the arterial phase with 
washout in the portal or delayed phases) is identified by using 
the imaging techniques mentioned above, a nodule ≥1 cm in 
Table 2. Continued
Topic Recommendation
Transarterial 
  chemoembolization 
  and other transarterial 
  treatments
1. TACE is recommended for patients with good performance status without major vascular invasion or extrahepatic 
spread who are ineligible for surgical resection, liver transplantation, RFA, or PEIT (A1).
2. TACE should be performed through tumor-feeding vessels using selective/superselective techniques to maximize an-
titumor activity and minimize hepatic damage (B1).
3. Chemoembolization using drug-eluting beads results in less systemic adverse events and has similar therapeutic ef-
ficacy compared with conventional TACE (B2).
4. In case of portal vein invasion, TACE can be considered for patients with localized tumor and well-preserved liver 
function (B2).
External-beam 
  radiation therapy
1. EBRT can be performed in HCC patients if liver functions are Child-Pugh class A or superb B and the irradiated total 
liver volume receiving ≥30 Gy is ≤60% (B1).
2. EBRT can be considered for HCC patients ineligible for surgical resection, liver transplantation, RFA, PEI, or TACE (C1).
3. EBRT can be considered for HCC patients who exhibit incomplete response to TACE when the dose-volume criteria 
in Recommendation 1 are met (B2).
4. EBRT can be considered for HCC patients with portal vein invasion when the dose-volume criteria in Recommenda-
tion 1 are met (C1).
5. EBRT is performed to alleviate symptoms caused by primary HCC or its metastases (B1).
Systemic therapies 1. Sorafenib is indicated for HCC patients with very well-preserved liver function (Child-Pugh class A), good per-
formance status, and regional lymph node or extrahepatic spread or for patients with tumor progression on other 
therapies (A1).
2. Sorafenib is recommended for HCC patients with very well-preserved liver function (Child-Pugh class A), good per-
formance status, and vascular invasion (A2).
3. Sorafenib is considered for HCC patients with liver function Child-Pugh class superb B and good performance status 
if the above conditions 1 and 2 are satisfied (B1).
4. Cytotoxic chemotherapy can be considered for HCC patients with advanced tumors who have with well-preserved 
liver function and, with good performance status, in whom sorafenib therapy has failed (C1).
5. Adjuvant TACE, sorafenib, or cytotoxic chemotherapy are not recommended for HCC patients treated with curative 
resection (B1).
Preemptive antiviral 
  therapy
1. Patients should be tested for the HBsAg before starting cytotoxic chemotherapy or immunosuppressive therapy (A1).
2. Preemptive antiviral therapy is recommended for HBV carriers undergoing cytotoxic chemotherapy to prevent re-
activation (A1). Preemptive antiviral therapy is considered for HBV-infected patients receiving TACE (B1), hepatic 
arterial infusion chemotherapy (C1), surgical resection (C1), or EBRT (C1) to prevent reactivation.
3. Antiviral treatment for HBV reactivation should follow the recommendations of the current KASL guidelines (A1).
Drug treatment for 
  cancer pain in HCC
1. Careful consideration is required for pain management with medication in patients with HCC and underlying liver 
disease. The dosage and dosing intervals of analgesics should be determined on the basis of liver functions (C1).
2. In patients with HCC and chronic liver disease, the dosage of acetaminophen should be lowered (C1) and NSAIDs 
should be used with caution (B1).
3. In patients with HCC and chronic liver disease, opioid analgesics and their dosage should be selected carefully on 
the basis of drug metabolism and liver function (C1).
Assessment of tumor 
  response and 
  posttreatment 
  follow-up
1. Assessment of tumor response should follow both the RECIST and modified RECIST criteria (B1).
2. Patients with complete response after treatment should be followed up with imaging studies (i.e., dynamic contrast-
enhanced CT/MRI or liver-specific contrast-enhanced MRI) and serum tumor markers every 2–6 months in the first 
2 years; thereafter, patients should be followed by regular checkups at individualized intervals (B1).
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; KASL, Korean Association for 
the Study of the Liver; CT, computed tomography; MRI, magnetic resonance imaging; TACE, transarterial chemoembolization; RFA, radiofrequen-
cy ablation; PEIT, percutaneous ethanol injection therapy; EBRT, external-beam radiation therapy; NSAIDs, nonsteroidal anti-inflammatory drugs; 
RECIST, Response Evaluation Criteria in Solid Tumors.
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diameter can be diagnosed as HCC. Low, medium, and high 
signal intensity in the hepatocyte phase, T2-weighted image, 
and diffusion-weighted image, respectively, have been sug-
gested as additional findings to support the diagnosis of HCC 
by MRI using a hepatocyte-specific contrast agent.56,57 However, 
further studies are required to confirm evidence on the role of 
these findings. The role of angiography in the diagnosis of HCC 
is quite limited owing to rapid advances in other noninvasive 
imaging techniques. Although contrast-enhanced ultrasonogra-
phy has been introduced to characterize and localize small liver 
nodules (especially for radiofrequency ablation), its roles in the 
diagnosis and staging of HCC remain quite limited.58 Positron 
emission tomography-CT (PET-CT) is not recommended as a 
primary diagnostic imaging method, because its diagnostic ac-
curacy is relatively low, especially in patients with small HCC.59
The accuracy of noninvasive diagnostic criteria largely de-
pends on the size of the nodules. As the size of the nodules 
increases, their differentiation becomes poorer.60,61 As an HCC 
lesion grows, it begins to exhibit the typical hallmark of HCC, i.e., 
hypervascularity in the arterial phase with washout in the portal 
or delayed phases due to the gradual growth of tumor arteries 
and regression of portal flow.55,61 Nowadays, small nodules <1 
cm in diameter showing the typical hallmark of HCC are being 
detected more frequently because of recent advances in imaging 
technologies. Many guidelines from Asia allow the diagnosis of 
HCC on the basis of these small nodules.45,48,62
The pathologic diagnosis of HCC requires an adequate speci-
men through biopsy. However, biopsy is not always feasible 
because of the location of the target lesion and potential risk of 
complications such as bleeding and tumor seeding, especially 
in cirrhotic patients. The diagnostic sensitivity of fine-needle 
aspiration cytology, fine-needle aspiration biopsy, and core 
needle biopsy are reported to be 67% to 93% but much lower in 
patients with small HCC <2 cm or targeting problems.63,64 As the 
risk of tumor seeding due to needle biopsy is reported to be 0.6% 
to 5.1%, the need for biopsy for patients with HCC curable by 
surgical resection is being challenged.65,66 In addition, the false 
negativity of biopsy is reported to be approximately 33%.64
The diagnosis of HCC for liver nodules detected by surveil-
lance is based on noninvasive criteria or pathology (Table 3, Fig. 
3). Noninvasive criteria can only be applied to high-risk groups 
(i.e., HBV/HCV infection and liver cirrhosis) and are based on 
imaging including dynamic CT, dynamic MRI, and MRI us-
ing a hepatocyte-specific contrast agent. Diagnosis should be 
based on the identification of the typical hallmark of HCC (i.e., 
hypervascularity in the arterial phase and washout in the por-
tal or delayed phase) for liver nodules ≥1 cm in diameter.45,62,67 
One or more imaging techniques are usually recommended for 
noninvasive diagnosis for these nodules; however, one or more 
imaging techniques are required in optimal settings (Appendices 
5 and 6), whereas two or more are recommended in subop-
timal settings for nodules 1–2 cm in diameter.58 In addition, 
stricter criteria are warranted for the diagnosis of HCC in cases 
of nodules <1 cm. Diagnosis should be based on the combina-
tion of the identification of the typical hallmark of HCC in two 
or more imaging modalities and increased serum AFP with an 
increasing trend over time for liver nodules <1 cm in patients 
with suppressed hepatitis activity.57 Biopsy should be considered 
for atypical nodules not meeting the noninvasive criteria. Any 
changes in the size or characteristics of nodules or serum tumor 
markers should be monitored if noninvasive or pathologic diag-
nosis is unfeasible for liver nodules in high-risk patients.
1. Diagnostic X-ray radiation exposure dose and risk of dy-
namic CT in HCC patients
A study of low-dose radiation in atomic bomb survivors indi-
cates a significant increase in cancer risk even from acute 10–50 
mSv radiation exposure.68 In addition, studies of occupational 
radiation exposure suggest protracted 50–100 mSv exposure 
can increase cancer risk in humans.69-71 The International Com-
mission on Radiological Protection (ICRP) reports that the can-
cer risk after radiation exposure exhibits a linear-nonthreshold 
dose–response relationship.72,73 However, there is no report on 
direct diagnostic X-ray radiation exposure-related cancer risk. 
The dose of radiation exposure of 4-phase liver dynamic CT is 
approximately 20–30 mSv. According to BEIR VII phase 2 trial 
by the Committee to Assess Heath Risks from Exposure to Low 
Levels of Ionizing Radiation, the additional lifetime attribut-
Table 3. Diagnosis of Hepatocellular Carcinoma
1. Noninvasive diagnosis: in high-risk groups (i.e., HBV/HCV infection, liver cirrhosis) 
   1) For liver nodules 1 cm found by surveillance: 
If the typical hallmark of HCC* is identified on one or more (two or more†) imaging techniques‡
   2) For nodules <1 cm found by surveillance: 
If the typical hallmark of HCC* is identified in two or more imaging techniques‡ and increased serum AFP with an increasing trend over time  
 is noted in patients with suppressed hepatitis activity 
2. Pathologic diagnosis
HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; AFP, a-fetoprotein.
*Hypervascularity in the arterial phase and washout in the portal or delayed phase; †For 1–2-cm nodules, the diagnosis should be based on the 
identification of the typical hallmark of HCC in one or more imaging techniques in optimal settings (Appendices 5 and 6) and in two or more 
imaging techniques in suboptimal settings; ‡Dynamic computed tomography, dynamic magnetic resonance imaging, gadolinium-ethoxybenzyl-
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging magnetic resonance imaging. 
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able solid cancer and leukemia incidence and mortality rates 
are 0.148% and 0.09%, respectively, in 50-year-old men with 
25 mSv X-ray radiation exposure after a 4-phase liver dynamic 
CT.74,75 The ICRP 2007 recommendations are as follows: “The 
limitation of the dose to the individual patient is not recommend-
ed because it may, by reducing the effectiveness of the patient’s 
diagnosis or treatment, do more harm than good. The emphasis is 
then on the justification of the medical procedures and on the op-
timization of protection.”76 Thus, considering the abovementioned 
factors, any limitation of the cumulative radiation dose from CT 
for the diagnosis and follow-up evaluation of HCC is invalid.
Recommendations (Table 2)
1. HCC is diagnosed on the basis of either pathology or clini-
cal criteria in case of the high-risk group (HBV/HCV positive or 
cirrhosis) (A1).
2. When HCC is suspected during surveillance in the high-
risk group, dynamic contrast-enhanced CT/MRI or liver-specific 
contrast-enhanced MRI should be performed for diagnosis (B1).
3. In the high-risk group, HCC can be diagnosed for nodules 
≥1 cm in diameter if one or two of the above-mentioned imag-
ing techniques show typical features of HCC (for the diagnosis 
of nodules 1–2 cm in diameter, two or more imaging modalities 
are required if a suboptimal imaging technique is used). Typical 
features of HCC include arterial phase enhancement with wash-
out in the portal or delayed phase (B1).
4. Nodules <1 cm in diameter can be diagnosed as HCC in 
high-risk patients when all of the following conditions are met: 
typical features of HCC in two or more of the above-mentioned 
imaging modalities and continuously rising serum AFP with 
hepatitis activity under control (C1).
5. Pathological diagnosis should be considered when the 
clinical criteria are not met or typical features of HCC are not 
present. The presence of indeterminate nodules despite imaging 
workups or pathologic examination needs to be followed up 
with repeated imaging and serum tumor marker analysis (B1). 
6. Limitation of radiation exposure in diagnosis and staging 
is not considered relevant in patients with HCC. CT is essential 
for diagnosis and follow-up in HCC patients (C1).
STAGING
Cancer staging plays a pivotal role in predicting prognosis 
as well as selecting the therapy to maximize survival potential. 
It also facilitates exchange of information and trial design. The 
prediction of prognosis in HCC patients is complex, because un-
derlying liver function also affects prognosis.77,78 Although sev-
eral staging systems for patients with HCC have been devised, 
there is no worldwide consensus.79
The American Joint Committee on Cancer (AJCC) has led 
a collaborative effort with the International Union for Cancer 
Control (UICC) to maintain a cancer staging system since 1959. 
This system classifies the extent of disease mostly on the basis 
of anatomic information on the extent of the primary tumor, 
regional lymph nodes, and distant metastases (i.e., TNM) and 
has been modified repeatedly. The Korean Liver Cancer Study 
Group and The Korea National Cancer Center have adopted the 
fifth version of the mUICC staging system as a primary staging 
system for HCC in 2003 (Table 4).80 Thus, the continuous use 
of this staging system since then may facilitate consistency in 
the analyses of registry data.62 The mUICC staging system ap-
pears more advantageous for estimating the prognosis of small 
HCC because it sets the size criterion to 2 cm unlike the AJCC/
UICC, which used a criterion of 5 cm.81 However, the fifth ver-
Mass/nodule in US surveillance for patients
with HBV+, HCV+, or cirrhosis+
<1 cm >1 cm
Continuously rising
serum AFP level with
hepatitis activity under
control
Yes No
One or two positive
thchniques of HCC
radiological hallmarks in
dynamic contrast enhanced
CT/MRI or Gd-EOB-DTPA MRI
YesNo
Yes No
HCC HCCBiopsy or follow-up
*
Two positive techniques of
HCC radiological hallmarks in
dynamic contrast enhanced
CT/MRI or Gd-EOB-DTPA MRI
*
Fig. 3. Diagnostic algorithm. 
US, ultrasonography; HBV, hepatitis 
B virus; HCV, hepatitis C virus; AFP, 
a-fetoprotein; HCC, hepatocellular 
carcinoma; CT, computed tomog-
raphy; MRI, magnetic resonance 
imaging; Gd-EOB-DTPA, gadolinium 
ethoxybenzyl diethylenetriamine 
pentaacetic acid. *HCC radiological 
hallmarks include arterial phase en-
hancement with washout in the portal 
or delayed phase; †For the diagnosis 
of nodules 1–2 cm in diameter, two or 
more imaging modalities are required 
if a suboptimal imaging technique is 
used.
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sion of the mUICC staging system has limitations, particular its 
lack of extensive validation and different criteria compared with 
those of the current seventh AJCC/UICC TNM staging system. 
In addition to dynamic CT or MR imaging of the primary liver 
tumor, chest CT, bone, and PET-CT scans may be required to 
stage HCC. The risk of distant metastasis is low for patients with 
early-stage HCC;82 therefore, tests for the evaluation of extrahe-
patic metastasis should be carefully selected. The direct or indi-
rect evaluation of portal hypertension is also required, especially 
for patients who are being considered for surgical resection.
The Barcelona Clinic Liver Cancer (BCLC) staging system in-
cludes factors for tumor stage, degree of liver function, and per-
formance status of the patient. It suggests the most recommend-
able treatment modality for each stage and is being endorsed 
by the American Association for the Study of Liver Diseases 
(AASLD), the European Association for the Study of the Liver 
(EASL), and the European Organisation for Research and Treat-
ment of Cancer (EORTC).58,83 However, the use of the BCLC stag-
ing system is limited because it contains a subjective component 
(i.e., performance status), crude evaluation of liver function (i.e., 
Child-Pugh class), and unduly simplified recommendations for 
treatment modality.
Recommendations (Table 2)
1. This guideline adopted the mUICC stages as a primary stag-
ing system, with the BCLC staging system serving as a comple-
mentary system (B1).
(1) Number of tumors:
solitary
Criteria T1 T2 T3 T4
(2) Diameter of the
largest tumor: no
more than 2 cm
(3) No vascular or bile
duct invasion: Vp0,
Vv0, B0
All three criteria
are fulfilled
Two of the three
criteria are
fulfilled
One of the three
criteria is fulfilled
None of the three
criteria are
fulfilled
Table 4. Modified Union for International Cancer Control Staging 
System*
Stage T N M
I T1 N0 M0
II T2 N0 M0
III T3 N0 M0
IV A T4 N0 M0
T1, T2, T3, T4 N1 M0
IV B T1, T2, T3, T4 N0, N1 M1
*Adapted from the Liver Cancer Study Group of Japan.80,81
Fig. 4. First-line treatment according to the 2014 KLCSG-NCC Korea 
Practice Guidelines for patients with HCC, Child-Pugh class A, no 
portal hypertension, and ECOG performance status 0–1.
KLCSG, Korean Liver Cancer Study Group; NCC, National Cancer 
Center; HCC, hepatocellular carcinoma; ECOG, Eastern Cooperative 
Oncology Group; mUICC, modified Union for International Cancer 
Control; RFA, radiofrequency ablation; TACE, transarterial chemo-
embolization; PEIT, percutaneous ethanol injection therapy; EBRT, 
external-beam radiation therapy; LT, liver transplantation; DDLT, 
deceased donor LT; LDLT, living donor liver transplantation; VI, vas-
cular or bile duct invasion. 
mUICC stage Alternative optionBest option
Resection
RFA
TACE
PEIT
EBRT
Single/<2 cm/VI-
RFA (tumor size <3 cm)
Resection TACE
EBRT
LT
Single/>2 cm/VI
DDLT (within Milan criteria)
TACE
RFA (tumor number <3)
Multiple/<2 cm/VI
Single/<2 cm/VI+
Multiple/>2 cm/VI
Single/>2 cm/VI+
Multiple/<2 cm/VI+
Multiple/>2 cm/VI+
Node+/no metastasis
Metastasis+
TACE
EBRT
Sorafenib
TACE
LT (within Milan criteria)
RFA (tumor number <3 and size
<3 cm)
TACE
Sorafenib
EBRT
TACE
Sorafenib
Sorafenib
Sorafenib
Sorafenib
Resection
LDLT
PEIT (tumor number <3)
Resection
Resection
Resection
TACE
TACE
EBRT
TACE
EBRT
I
II
II
II
III
III
III
IVa
IVa
IVb
KLCSG and NCC: Practice Guideline for Hepatocellular Carcinoma  277
TREATMENT OVERVIEW
The ultimate goal of treatment for HCC is improvement of 
patient survival. This requires multidisciplinary treatment plan-
ning including hepatology, oncology, surgery, diagnostic and 
interventional radiology, radiation oncology, and pathology. 
Therapies should be selected on the basis of strong evidence 
such as meta-analyses including randomized controlled trials 
(RCTs), prospective controlled studies, and prospective large-
scale cohort studies, all of which have survival as an endpoint. 
However, RCTs regarding HCC are limited. Therefore, currently 
available evidence should be interpreted cautiously. For bal-
anced multidisciplinary treatment planning, objective evalua-
tion is necessary in clinical practice.
The recommendations in this guideline were derived from 
the current best available evidence. Prerequisites for the ap-
plication of these recommendations include equipment, trained 
personnel, and financial resources; considering the varying lev-
els of these prerequisites among facilities, best and alternative 
options are proposed herein (Fig. 4). As the treatment options 
presented herein do not encompass all possible situations, spe-
cific treatments should be selected on the basis of tumor state, 
liver function, cirrhotic complications, and performance status. 
Recommendations for specific treatments are made on the basis 
of evidence and expert opinions, and are described in detail 
elsewhere in this guideline.
This overview summarizes treatment options for patients in 
various mIUCC stages with well-preserved hepatic function (i.e., 
Child-Pugh class A) and good performance status, without any 
complications of portal hypertension. In addition, this guideline 
mainly includes initial treatment options for HCC at first di-
agnosis, without covering re-treatments for residual tumors or 
recurrence after initial treatment.
HEPATIC RESECTION
Hepatic resection is not only a primary treatment option for 
HCC unaccompanied by liver cirrhosis,84 but should also be 
preferentially considered even for HCC with cirrhosis if the liver 
function is expected to be able to tolerate surgery.85,86 The results 
of hepatic resection for HCC have markedly improved thanks to 
recent advances in preoperative tests and surgical skills as well 
as accumulation of experience in postoperative management.87 
Recent studies show that postoperative mortality after HCC re-
section is less than 1%–3%. In addition, the 5-year overall and 
disease-free survival rates are 46%–56% and 23%–32%, respec-
tively.88-90
Child-Pugh classification is conventionally used to preopera-
tively assess the safety of hepatic resection (Table 5).91 Hepatic 
resection is commonly performed in patients with Child-Pugh 
class A with Eastern Cooperative Oncology Group (ECOG) per-
formance status 0–2 (Table 6). However, Child-Pugh classifi-
cation is an insufficient preoperative indicator of operability, 
because many patients can remain in Child-Pugh class A de-
spite advanced cirrhosis.92,93 Therefore, the indocyanine green 
15-minute retention rate (ICG-R15), which was suggested in 
Japan, is evaluated at many Korean institutions as a preopera-
tive test for the prediction of residual liver function.94 Although 
major hepatic resection is recommended only for patients with 
ICG-R15 ≤10%, some authors recently reported safely perform-
ing right hemihepatectomy even in patients with an ICG-R15 of 
14%.95 On the other hand, portal hypertension and serum biliru-
bin level have been suggested to be important indicators for the 
assessment of resectability in Europe and the USA. Portal hy-
pertension is defined as a hepatic venous pressure gradient ≥10 
mm Hg.96 Esophageal varix and thrombocytopenia <100,000/
mm3 accompanied by splenomegaly are also indicators of portal 
hypertension, and thrombocytopenia is considered the most 
clinically useful.58 The posthepatectomy complication rate is 
Table 5. Child-Pugh Classification
1 2 3
Albumin, g/dL >3.5 2.8–3.5 <2.8
Bilirubin, mg/dL <2.0 2.0–3.0 >3.0
Prothrombin time prolonged, sec 0–4 4–6 >6 
Ascites None Slight Moderate
Encephalopathy, grade None 1–2 3–4
Class A ≤6 points, Class B=7–9 points, Class C ≥10 points.
Table 6. Eastern Cooperative Oncology Group Performance Status*
Grade ECOG
0 Fully active, able to carry out all pre-disease performance without restriction
1 Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house 
  work, office work
2 Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot perform any self-care. Totally confined to bed or chair
5 Dead
ECOG, Eastern Cooperative Oncology Group.
*Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
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high and the long-term prognosis is poor in patients with portal 
hypertension.96-98 However, some recent studies show compa-
rable outcomes can be achieved even in patients with portal hy-
pertension.99-101 Therefore, hepatic resection can also be consid-
ered the primary treatment option in patients with mild portal 
hypertension if LT is unavailable. Minor hepatic resection less 
than hemihepatectomy should be considered in patients with 
mild portal hypertension, because resection volume is closely 
associated with the risk of postoperative hepatic insufficiency.
Assessment of future liver volume or remnant liver volume 
after resection is as important as the hepatic reservoir func-
tion test in order to predict postoperative hepatic insufficiency. 
HCC is accompanied by chronic liver disease in 80% of cases. 
Although 70%–80% of the liver’s volume can be resected for 
normal livers, much less resection volume is allowed for dis-
eased livers. There are few studies about the safe remnant liver 
volume in patients with cirrhosis. Nevertheless, a remnant liver 
volume ≥40% is generally recommended in cirrhotic patients 
for safety.102 Several noninvasive tests to measure the severity 
of hepatic fibrosis have been developed. Among them, transient 
elastography was recently reported to be effective for predicting 
postoperative hepatic failure.103-105 In the near future, transient 
elastography is expected to play an important role in the preop-
erative assessment of hepatic functional reservoir.
Dynamic contrast-enhanced CT is the basic test utilized as 
a preoperative radiologic study to assess the possibility of re-
section. MRI using a hepatic cell-specific contrast medium is 
superior to CT for HCC detection, especially for small HCCs <1 
cm.106,107 Nevertheless, more studies are required to validate the 
value of MRI as the basic radiologic study for assessing resect-
ability and formulating resection plans. Further postoperative 
examinations may be necessary to find extrahepatic metastases 
in patients with advanced HCC. 18F-fluoro-2-deoxyglucose (18F-
FDG) PET-CT may be effective for investigating extrahepatic 
metastasis, although its sensitivity is very low for intrahepatic 
lesions.59,108 In addition, chest CT and bone scan may be help-
ful.109
Transarterial chemoembolization (TACE), performed before 
hepatic resection for the purpose of improving postoperative 
prognosis, is not recommended.110,111 Some reports assert that 
portal vein embolization before extensive hepatic resection 
might induce compensatory hypertrophy of the residual liver 
and reduce the risk of surgery, especially in cases with liver cir-
rhosis; nonetheless, these are largely debatable.112,113
One reason why hepatic resection has recently become safer is 
the reduction in the amount of intraoperative hemorrhage, thus 
minimizing the amount of blood transfusion required. Blood 
transfusion compromises anticancer immunologic mechanisms 
and increases postoperative recurrence. A recent meta-analysis 
reports that intraoperative transfusion increases complication 
rates and reduces overall and disease-free survival rates after re-
section in HCC patients.114 Owing to selective hepatic blood flow 
occlusion, maintaining low central venous pressure, and precise 
transection of the hepatic parenchyma, the recent rate of trans-
fusion in hepatic resection is ≤10%.115 Although some reports 
suggest anatomical resection may be superior to nonanatomi-
cal resection by securing the resection margin and removing 
micro-metastases,116 further confirmation is required, because 
the results are inconsistent.117 Surgery guaranteeing a tumor-
free resection margin is absolutely critical for improving long-
term prognosis. One prospective randomized trial shows that 
a resection margin >2 cm leads to better outcomes after HCC 
resection.118 Meanwhile, another study reports that the resec-
tion margin width is not important so long as a tumor-negative 
margin is guaranteed.119 Therefore, although sufficient margin 
from the tumor and anatomical resection are recommended dur-
ing HCC resection if possible, considering patient safety is more 
important, because excessive hepatic resection can be fatal in 
patients with cirrhosis.116,120,121
Laparoscopic hepatic resection has advanced rapidly, and its 
indications have been expanded. Many studies show that the 
efficacy and safety of laparoscopic hepatic resection is compa-
rable to those of open hepatic resection for small HCCs located 
in the left lateral section or on the surface of the right liver.122 
Although laparoscopic major hepatic resection is increasingly 
being performed as well, it is currently limited to only experi-
enced surgeons. Accordingly, its efficacy and safety should be 
evaluated further.123 Robotic hepatic resection has recently been 
tried in very select cases, and comparative studies between ro-
botic hepatic resection and open or laparoscopic hepatic resec-
tion are expected.124
The best prognosis after hepatic resection is generally ex-
pected in cases involving 1 or 2 small tumors. Larger tumors 
are associated with a high incidence of vascular invasion result 
in poor prognosis even after resection. However, a recent study 
shows that approximately one-third of large HCCs ≥10 cm have 
no vascular invasion and favorable results after resection in 
those cases. Therefore, the resectability for HCC should not be 
decided upon according to tumor size.125-127 Recent advances 
in surgical techniques and improvements in patient manage-
ment have enabled hepatic resection in elderly patients with 
comparable short- and long-term outcomes. Nevertheless, major 
hepatic resection should be considered with caution, because 
hepatic regeneration power gradually decreases with age.128-130
Although some authors reported that one-stage hepatic resec-
tion was an effective method for ruptured HCC in patients with 
good liver function,131 first hemostasis by TACE and subsequent 
elective surgery after accurate assessment of hepatic reservoir 
function would be safer and more effective in hemodynami-
cally unstable patients.132,133 However, ruptured cases have 
poorer long-term results than unruptured HCC cases.134 Hepatic 
resection is generally contraindicated in cases with evident tu-
mor invasion to major hepatic or portal veins. In patients with 
less hepatic fibrosis or those with a well-differentiated HCC of 
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low Edmondson-Steiner grade, the 5-year survival rate after 
resection of HCC with major vascular invasion is reported to 
be ≥20%.135 Nevertheless, surgical resection would be at least 
more effective than medical treatment.136 According to a Korean 
multicenter study, the 5-year survival rate after resection of 
HCC with bile duct invasion was satisfactory at 32%.137 Hence, 
surgical resection can be considered even for HCC with major 
vascular invasion or bile duct invasion in select cases.
The hanging maneuver is frequently used during hepatic 
resection. However, there is no report about the effect of the 
hanging maneuver on survival or recurrence after HCC resec-
tion. Nevertheless, the hanging maneuver can shorten operative 
time and reduce the amount of bleeding.138 The anterior ap-
proach, which is often used for the resection of large tumors, is 
associated with less bleeding, a lower transfusion rate, and bet-
ter survival in one prospective study.139 However, its pathologic 
advantages require further evaluation.
The 5-year recurrence rate after hepatic resection of HCC 
ranges from 58% to 81%, and 80% to 95% of postoperative re-
currences are intrahepatic.140 Intrahepatic recurrences are divid-
ed into intrahepatic metastasis and de novo HCC by multicentric 
carcinogenesis. The two recurrence entities can be differentiated 
by means of genomic hybridization, DNA fingerprinting, DNA 
microarray, or HBV integration pattern.141 However, no clini-
cal definition of either entity has been established. In general, 
late recurrence more than 2 years after primary resection is 
considered de novo HCC.142 Risk factors associated with recur-
rence after resection are classified as tumor-related factors and 
underlying disease-related factors. Tumor-related risk factors, 
which are usually related to early recurrence, include tumor size 
and number, microvascular invasion, poor tumor differentia-
tion, high serum AFP and PIVKA-II levels, and positivity on 18F-
FDG PET. Meanwhile, underlying disease-related risk factors, 
which influence late recurrence, include cirrhosis, high serum 
HBV DNA level, and active hepatitis.59,142-148 Nevertheless, no as-
sociation between risk factors and recurrence time is evident in 
many cases, because this time-dependent classification does not 
actually reflect the tumor-pathologic mechanism of HCC recur-
rence.
Imaging modalities such as CT and MRI as well as serum tu-
mor markers are recommended surveillance tools during follow-
up. Serum AFP, a traditional tumor marker of HCC, is not only 
useful for the diagnosis of HCC, but is also effective for checking 
for recurrence after resection. PIVKA-II is another HCC marker 
with increasing utility for diagnosis, follow-up, and prognostica-
tion of HCC.147,149
The 5-year survival rate of patients who undergo re-resection 
of intrahepatic recurrence after initial surgery ranges from 37% 
to 70%.140,150-152 Because the result of re-resection is excellent 
in cases with a long interval between initial surgery and tumor 
recurrence, re-resection can be recommended particularly for 
patients with late intrahepatic recurrence 1–2 years after initial 
resection as long as vascular invasion of the tumor is not evi-
dent and liver function is tolerable to re-operation. In addition, 
salvage transplantation could result in an excellent disease-free 
survival rate >60% if the conditions of the patient and recurrent 
tumors are suitable for transplantation.153,154 Extrahepatic recur-
rence develops in 15%–37% of cases after HCC resection, most 
frequently in the lungs followed by the abdominal cavity and 
bones.155 Metastatectomy can also be considered when the liver 
function can tolerate surgery and intrahepatic HCCs have been 
clearly treated or are controllable.156,157
Recommendations (Table 2)
1. Surgical resection is the first-line treatment for patients 
with intrahepatic single-nodular HCC and well-preserved liver 
function of Child-Pugh class A without portal hypertension or 
hyperbilirubinemia (A1).
2. Limited resection can be selectively applied to HCC patients 
with liver function Child-Pugh class A or superb B and with 
mild portal hypertension or mild hyperbilirubinemia (C1).
3. HCC Resection can be considered in patients with three or 
fewer intrahepatic tumors without macrovascular invasion if 
hepatic function is well preserved (C2).
4. Laparoscopy-assisted resection can be considered for HCC 
located in the lateral section of the left lobe or anterolateral seg-
ment of the right lobe (B2).
LIVER TRANSPLANTATION
LT is the first choice of treatment for patients with single tu-
mors ≤5 cm or those with small multinodular tumors (≤3 nod-
ules ≤3 cm) and advanced liver dysfunction. LT involves com-
plete removal of a diseased liver including HCC and replacement 
with another liver. It is theoretically the ideal treatment method. 
The application of broad selection criteria in the early history of 
LT resulted in very poor outcomes, with a 5-year survival less 
than 40%; there was even a time when LT was relatively con-
traindicated.158,159 However, this resulted in the identification of 
the best candidates, and subsequent studies with highly specific 
groups of patients report a 5-year disease-free survival rate of 
74%.160,161 The Milan Group in Italy reports excellent results af-
ter LT, showing that patients with the following characteristics 
have 4-year survival and disease-free survival rates of 75% and 
83%, respectively: (1) no extrahepatic metastasis or vascular 
infiltration in radiologic study before LT; (2) a single nodule 
≤5 cm; (3) ≤3 nodules in cases of multiple nodules, with each 
nodule ≤3 cm. Accordingly, they suggest those criteria for LT in 
patients with HCC.162 Since then, the Milan criteria have widely 
been applied for LT in patients with HCC. A recent systematic 
review of 90 studies including a total of 17,780 patients over 15 
years identified the Milan criteria as an independent prognos-
tic factor after LT. The overall 5-year survival rate of patients 
meeting the Milan criteria (65%–78%) is similar to that of non-
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HCC patients according to European and American transplant 
registries.163-165
Recent advances in imaging technologies have enabled the 
noninvasive diagnosis of HCC with higher accuracy. However, 
small lesions that could not be detected by imaging studies 
when the Milan criteria were established can often be seen on 
imaging studies using current technologies, causing confusion 
as to whether a patient meets the Milan criteria or not. A recent 
meta-analysis including 22,392 patients concludes that the size 
of the largest tumor and total diameter of nodules are the best 
predictors of outcome but that there is insufficient evidence 
regarding the effect of nodule number on the outcome of LT.166 
Sugimachi et al.167 also report poor diagnostic accuracy of ra-
diologic imaging for small (<1 cm) HCCs and their small effect 
on prognosis after LT. Therefore, lesions ≤10 mm or showing 
atypical imaging features should not be considered when decid-
ing upon LT.
Before LT, patients with HCC undergo tests for staging in ad-
dition to general whole-body examination. Dynamic contrast-
enhanced CT or MRI is performed as a radiologic assessment 
of the liver itself. Extrahepatic staging should include chest 
CT, and abdominal and pelvic CT or MRI.168 Brain imaging and 
bone scintigraphy can also be performed. Moreover, 18F-FDG 
PET-CT can help clarify the biologic characteristics of HCC, 
because PET-positive tumors exhibit unfavorable histological 
features more frequently (e.g., high cellular dedifferentiation 
and microvascular invasion), resulting in worse recurrence-free 
survival after LT.169,170 Although there is neither a specific study 
nor consensus on the optimal timing or modality of evaluation 
of wait-listed patients to ensure they continue to meet the ac-
ceptability criteria for LT, re-evaluation with a 3-month interval 
is commonly performed with dynamic CT or MRI and AFP mea-
surement.171
1. Deceased donor liver transplantation
Deceased liver donors are always in shortage. Accordingly, 
many patients are waiting for LT at any given time. Patients 
with HCC must undergo a long waiting period from registration 
to LT. The American United Network for Organ Sharing (UNOS) 
introduced the Model for End-stage Liver Disease (MELD) scor-
ing system in order to decide on the priority order for LT. Pa-
tients with HCC involving a single nodule between 2 and 5 cm 
or multinodular tumors (≤3 nodules ≤3 cm) are given the prior-
ity MELD score of 22 points as well as 10% additional points 
for every 3 months waiting for LT; thus, similar risks of drop-
out from the waiting-list can be expected between HCC patients 
and non-HCC candidates.172,173 Meanwhile, Korean the National 
Organ Transplantation Management Center operates the Korean 
Network for Organ Sharing (KONOS) grading system.174 In this 
system, no additional points are given to patients with HCC. 
The provision in the KONOS grading system regarding patients 
with HCC specifies that cases with a Child-Turcott-Pugh score 
≥7 points and simultaneously meeting the Milan criteria belong 
to KONOS grade 2B. Patients with KONOS grade 2B are pushed 
back in the priority order, and will not be able to undergo LT 
in a short time.175 According to a recent multicenter study in 
Korea (n=1,101; mean follow-up, 349 days), 23.5% of wait-
listed patients with HCC dropped out. The most frequent reason 
for dropping out was aggravation of liver function (46.7%), 
followed by aggravation of HCC (36.3%). Aggravation of HCC 
was observed in 44.8% (241/538) of patients while on the wait-
ing list; 14.2% and 48.1% of aggravations occurred within 1 
year and between 1 and 2 years after listing, respectively.176 The 
overall survival of patients with HCC was significantly worse 
than that of patients without HCC. The impact of HCC on the LT 
waiting list drop-out rate was significant only in patients with a 
MELD score <20.176,177
If the cutoff for the definition of a cure is a 5-year survival 
rate of 50% after LT in patients with HCC, the indications for LT 
could be expanded beyond the Milan criteria.178,179 Some studies 
chose a 5-year survival rate cutoff of 70%, because it is similar 
to the rate expected for patients undergoing LT for noncancer-
ous conditions and liver grafts from deceased donors.180-182 The 
University of California, San Francisco (UCSF) Group reports a 
5-year survival rate of 75% for patients meeting the following 
criteria: (1) a single tumor ≤6.5 cm; (2) <3 nodules in multiple 
HCC cases, with the longest diameter <4.5 cm and the sum of 
diameters <8 cm.183 In addition, the “up-to-seven criteria,” (i.e., 
the number 7 as the sum of the largest tumor diameter plus the 
number of tumors) have also been suggested; the 5-year sur-
vival rate of patients meeting these criteria is 71.2%.184 Micro-
vascular invasion in pretransplant biopsy, tumor volume, and 
AFP levels are also considered in the expanded indications for 
LT.185,186
2. Bridging therapy
The actuarial probability of dropping due to tumor progres-
sion while waiting for LT for 1 year is reported to range from 
15% to 30%.183 Locoregional therapies are reported to reduce 
the dropout rate to 0%–25%.173,187 TACE or radiofrequency abla-
tion (RFA) can be performed to prevent tumor progression.188-190 
Markov-based cost-effectiveness analysis indicates benefits 
for neo-adjuvant treatments when waiting times exceed 6 
months.188 AFP increasing >15 μg/L/mo while waiting for LT is 
the most relevant preoperative prognostic factor for low overall 
survival and disease-free survival.185
The effects of neoadjuvant treatments on survival after LT 
are even more difficult to assess. Many studies report survival 
rates similar to those of untreated individuals;191-194 however, 
the major limitation of these studies is shorter waiting times 
(<6 months) for LT.191,192 The response to bridging therapy sig-
nificantly affects both tumor recurrence and overall survival 
rate. This result suggests that HCC candidates should be priori-
tized with respect to their response to bridging therapy195 that 
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improved overall survival after LT is expected.196 The Organ 
Procurement and Transplantation Network/Scientific Registry of 
Transplant Recipients data regarding LT for HCC show a higher 
3-year post-LT survival rate in patients who received ablative 
procedures before LT than those who did not regardless of pre-
LT treatment modality.197 Radiation as a bridge to LT for ad-
vanced HCC is feasible, and well-selected patients are expected 
to achieve improved overall survival if HCC responds.198-200
3. Downstaging
Regarding downstaging, there are no randomized controlled 
trials, large case-control studies, or large well-designed cohort 
studies in which patients were treated consistently and properly 
followed up. Some prospective studies suggest downstaging ac-
cording to the Milan or UCSF criteria as a result of locoregional 
therapies achieves 5-year survival outcomes similar to those 
within the Milan or UCSF criteria.190,201 However, it is unclear 
if downstaging therapies yield measurable anticancer effects. 
Downstaging of HCC with TACE may be possible in 24%–63% 
of cases.178,196,202,203 Downstaging is more effective in cases in 
which tumor size is <7 cm or there are fewer than 3 tumors,203 
but there is no clear upper limit for the eligibility of downstag-
ing.204 Downstaging is possible with RFA or hepatic resection, 
but the efficacy of both remains inconclusive.187 Transarterial 
radioembolization (TARE) using 90Y appears to outperform TACE 
for downstaging HCC from UNOS T3 to T2, and downstaged 
patients show a statistically insignificant trend toward improved 
overall survival after LT.205
4. Living donor liver transplantation
Patients with HCC in Korea have a very low probability of 
receiving deceased donor liver transplantation (DDLT) before 
tumor progression.206 According to the KONOS regulation for 
registration and allocation in Korea, LT recipient candidates 
with HCC cannot gain higher priority on the waiting list.174 
These findings suggest DDLT is not a feasible treatment modal-
ity for patients with HCC in Korea. Therefore, living donor liver 
transplantation (LDLT) from a healthy donor has emerged as 
an alternative to DDLT as a treatment modality for HCC. In fact, 
a significant proportion of the LT recipients with HCC received 
transplantations from live donors in Korea. The proportion of 
adult LDLT recipients with HCC has recently increased to 30%–
40% in Korea, suggesting LDLT is now one of the main treatment 
modalities for HCC.207
The outcome of LDLT versus DDLT for patients with HCC is 
controversial. A meta-analysis of 633 LDLTs and 1,232 DDLTs208 
indicates LDLT is an acceptable option that does not compro-
mise survival rates. However, the disease-free survival rate is 
worse after LDLT than DDLT. The higher recurrence observed 
after LDLT is likely due to differences in tumor characteristics, 
pretransplant HCC management, and waiting time.209-211 The re-
currence rate with respect to stage is higher in recipients whose 
transplants were accelerated (i.e., “fast-tracked”) by perform-
ing LDLT, especially in the era in which patients with HCC are 
disadvantaged by the allocation algorithm.210 Cost-effectiveness 
studies suggest LDLT can be offered to patients with HCC if the 
waiting list exceeds 7 months.211 Some authors recommend an 
observation period, e.g., 3 months prior to LT, in order to avoid 
transplantation in cases with potentially aggressive tumors.210 
However, these propositions require further investigation. Fur-
thermore, future studies must have better study design and 
reporting in order to accurately describe the observed difference 
in disease-free survival due to inappropriate study design or 
biological risk specifically associated with LDLT.208 
Several eligibility criteria besides the Milan criteria for LDLTs 
have been adopted by many high-volume LDLT centers. At 
Asan Medical Center, patients with ≤6 HCCs ≤5 cm and without 
gross vascular invasion are considered eligible for LT; such pa-
tients have a 5-year survival rate of 81.6% at this center.212 At 
Seoul Catholic Medical Center, LDLT is considered the preferred 
therapeutic option in patients with an AFP level <100 ng/mL 
and a tumor diameter <5 cm. The 5-year disease-free survival 
and overall survival rates after LDLT in all patients with HCC are 
80.9% and 76.4%, respectively.213 At Seoul National University 
Hospital, the 3-year survival rate is reported to be 86.2% if vas-
cular invasion was absent in preoperative radiological studies 
and preoperative AFP was <400 ng/mL.214 At Samsung Medi-
cal Center, patient selection according to tumor size <5 cm and 
AFP <400 ng/mL without limitation of tumor number expanded 
patient selection; 1-, 3-, and 5-year survival rates are reported 
to be 92.2, 82.6, and 79.9%, respectively.215 In the selection of 
HCC patients for LT, the University of Tokyo has adopted the 
5-5 rule, i.e., HCC ≤5 cm and ≤5 in number, and a recurrence-
free survival rate of 94% after LT was achieved.216 Kyoto Uni-
versity further extended the number of tumors to 10 with serum 
PIVKA-II levels ≤400 mAU/mL; the resultant 5-year survival 
rate was 86.7%.217 At Kyushu University, a 5-year survival rate 
of 82.7% was achieved in patients with HCCs ≤5 cm and se-
rum PIVKA-II levels <300 mAU/mL.218 In a study involving 49 
centers and 653 patients in Japan, patients with HCCs beyond 
the Milan criteria but with serum AFP levels ≤200 ng/mL and 
serum PIVKA-II levels ≤100 mAU/mL had a 5-year disease-free 
survival rate of 84.3%.219
LDLT has been proposed as an ideal setting for exploring ex-
panded indications for HCC, considering a lack of graft alloca-
tion and priority policies. Moreover, the graft of a live donor is 
a personal gift. If the posttransplant outcomes of several eligible 
criteria beyond the Milan criteria for LDLTs are comparable to 
those with the Milan criteria, expanded indications can be ac-
cepted as long as the safety of the live donor is ensured. The 
5-year overall and disease-free survival rates of expanded in-
dications beyond the Milan criteria for LDLTs exceed 80% and 
70%, respectively.220-222
The outcomes of live donors (n=2,872 published cases) from 
282  Gut and Liver, Vol. 9, No. 3, May 2015
Korea are excellent.223-228 The risks and benefits of LDLT should 
take into account both the donor and recipient; this concept is 
known as “double equipoise.” The associated probabilities of 
death and life-threatening complications in LDLT for healthy 
donors are reported to be 0.3% and <2%, respectively.220-222,229 
Because of the complexity of the procedure, LDLT must be re-
stricted to centers of excellence in hepatic surgery and LT to 
minimize donor risk and maximize recipient outcome. Careful 
attention should be given to the psychosocial aspects of live do-
nors.
5. Salvage liver transplantation
Salvage liver transplantation (SLT) is promoted as a potential 
curative treatment strategy for HCC recurrence following pri-
mary liver resection with curative intent.230 This strategy may 
reduce disease progression in patients waiting for LT and may 
also reduce the number of transplants required. An intention-
to-treat analysis shows that LT for patients with small resectable 
HCCs yields survival outcomes superior to those of liver resec-
tion.231-233 Nevertheless, patients with small resectable HCCs are 
offered liver resection rather than LT because of the aforemen-
tioned organ shortage.234
Patients with HCCs beyond as well as within the Milan criteria 
should be initially treated with liver resection and can later be 
salvaged with LT if they develop recurrent HCC within the Milan 
criteria and is not too aggressive.153 The selection criteria for SLT 
are same as those for primary LT.153,154,232,235-239 This is because 
the risk factors for HCC recurrence after SLT are similar to those 
of primary LT.236,240 Significant independent risk factors for HCC 
recurrence after SLT include microscopic vascular invasion, poor 
differentiation, satellite nodules, high AFP level, and tumor size 
and number. Extension beyond the Milan criteria and avoiding 
risk factors are also important issues regarding SLT. Further-
more, prophylactic or preemptive SLT before HCC recurrence for 
patients with risk factors for recurrence after hepatic resection 
remains controversial in light of the organ shortage. Another 
concern is the potential for surgical difficulty following prior re-
section and postoperative complications, which may negate the 
benefit of an SLT. Meta-analyses and systemic reviews154,234,241 
show that the recipient outcomes of SLT are similar to those of 
primary LT with respect to overall and disease-free survival.
For patients who develop recurrent HCC after primary hepatic 
resection but have a very low probability of receiving DDLT 
before tumor progression, salvage LDLT could be a curative treat-
ment option like primary LT. The indications and selection criteria 
for salvage LDLT are same as those for primary LDLT.153,236-239
6. Posttransplantation immunosuppression
A calcineurine inhibitor-based immunosuppressant is gener-
ally administered in HCC patients after LT.242 Sirolimus was re-
cently reported to suppress HCC recurrence via an antiprolifera-
tion effect243,244 contributing to improved survival.245 However, 
this finding must be corroborated by additional studies.
Recommendations (Table 2)
1. DDLT is the first-line treatment for patients with single-
nodular HCC <5 cm in diameter or 3 or fewer ≤3 nodules ≤3 cm 
in diameter (Milan criteria), which are not indicated for resec-
tion (A1).
2. Locoregional therapies (local ablation or TACE) are recom-
mended if the timing of transplantation is not predictable (B1).
3. Downstaging (e.g., with TACE) can be considered for HCCs 
exceeding the criteria for transplantation (C2).
4. LDLT is an effective alternative to deceased donor trans-
plantation (B1).
5. An expanded indication for transplantation beyond the 
Milan criteria can be considered in HCC cases without definitive 
vascular invasion or extrahepatic spread, if other effective treat-
ment options are not inapplicable (C2).
6. Salvage transplantation can be indicated for recurrent HCC 
after resection according to the same criteria as for first-line 
transplantation (B1).
LOCOREGIONAL THERAPIES
Locoregional therapies are widely performed as nonsurgical 
treatments for HCC because of their convenience and relatively 
lower invasiveness. Although TACE can be considered a locore-
gional therapy in a broad sense, it will not be discussed here. 
RFA and percutaneous ethanol injection therapy (PEIT) are the 
current standard local therapies, while others such as micro-
wave ablation, laser ablation, cryoablation, acetic acid injection 
therapy, and high-intensity focused ultrasound are currently 
undergoing clinical trials.
The indications for locoregional therapies include patients 
with a single HCC nodule ≤5 cm or up to 3 nodules ≤3 cm, 
although they vary among studies. The effectiveness of local 
therapies depends on tumor size, while complete tumor necrosis 
rates are reported to exceed 80% for tumors <3 cm.246 Predictors 
of survival include initial complete tumor necrosis, Child-Pugh 
score, tumor size and number, and baseline serum AFP level. 
In particular, local therapies are very effective for Child-Pugh 
class A patients with single small HCC nodules <2 cm, although 
surgical resection is the standard treatment for such tumors.82 
Some researchers assert local therapies should be the primary 
treatments for these tumors because of the favorable tumor re-
sponse; however, this remains controversial.247 Local therapies 
are less effective for larger tumors, but efforts to improve them 
are being made. Contraindications for local therapies include 
corrected platelet count <50×103/mm3 and low prothrombin 
time (≤50%).
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1. Radiofrequency ablation
RFA is currently the most widely used ablation technique for 
the treatment of HCC. Very fast alternating currents (460 to 500 
kHz) flow in the vicinity of radiofrequency electrodes, inducing 
internal friction among molecules. The internal heat gener-
ated by the internal friction can evoke tissue necrosis. Heating 
to 60oC can cause almost immediate protein denaturation and 
destruction of cell membranes followed by coagulative necrosis. 
Heating to 45oC–50oC for ≥3 minutes can also cause similar ne-
crotic effects.
The main advantage of RFA is that fewer treatment sessions 
are required to achieve complete tumor necrosis. For HCC nod-
ules >2 cm, RFA results in a higher complete tumor necrosis 
rate than PEIT;248-251 most procedures were performed via a per-
cutaneous approach, although a laparoscopic or open surgical 
approach may be required in some instances. Initial complete 
tumor necrosis rates on imaging studies are reported to exceed 
96% and if RFA procedures are repeated for residual viable 
tumors, a complete tumor necrosis rate of almost 100% can be 
achieved.250 However, the estimated 3-year local tumor progres-
sion rate after RFA ranges widely from 0.9% to 21.4%.247,252,253
Despite these favorable outcomes, RFA has some disadvan-
tages. First, the risk of major adverse events is usually higher 
than that with PEIT, particularly when the tumors are located 
near the liver hilum or a major abdominal organ such as the 
large intestine. In addition, the heat sink effect may hinder ef-
fective transmission of heat energy to the tumor in cases in 
which the tumors are adjacent to relatively large intrahepatic 
vessels.251,254,255 However, the risk of thermal injury to the adja-
cent abdominal organs can be overcome by inducing artificial 
ascites.256 Another major limitation of RFA is that HCC nodules 
<2 cm may not be visible on conventional ultrasonography. 
However, recent applications of ultrasound contrast agents and 
fusion imaging techniques have broadened the indications for 
RFA to such cases.257,258
The mortality rate due to procedure-related complications 
after RFA is reported to be 0.1%–0.5%, and the major com-
plication rate after RFA is <5%.247,254,255 Major complications 
include needle tract seeding, hemoperitoneum, hemothorax, 
liver abscess, massive infarction of liver parenchyma, intestinal 
perforation, pneumoperitoneum, etc.253 The long-term survival 
outcomes of HCC patients can vary after RFA with respect to tu-
mor size. For Child-Pugh class A cirrhotic patients with tumors 
<2 cm, the 3- and 5-year overall survival rates after RFA are 
reported to be approximately 90% and 65%–70%, respective-
ly;247,252,253 meanwhile, those for tumors 2–5 cm are 65%–75% 
and 50%, respectively.252,253 The 10-year overall survival rate of 
Child-Pugh class A patients with single HCC <3 cm is 41.3%.253
In four RCTs comparing RFA and PEIT for patients with 
HCC,249-251,259,260 patients treated with RFA showed better lo-
cal tumor response and overall survival outcomes than those 
treated with PEIT. A meta-analysis of these four RCTs also 
demonstrates that the 3-year overall survival rate of RFA is sig-
nificantly higher than that of PEIT.261 Nevertheless, for patients 
with HCC <2 cm, there is no significant difference in survival 
outcomes between RFA and PEIT. Therefore, further prospective 
controlled studies are required.
As it is difficult to compare observational studies evaluating 
the long-term survival outcomes of RFA and surgical resection, 
it is not adequate to draw a definite conclusion regarding the 
superiority of either treatment. Three RCTs have recently been 
published on this topic. There were no significant differences in 
the survival outcomes between the two treatments in one RCT 
for solitary HCC <5 cm and another RCT for single or double 
HCCs <4 cm.262,263 However, the other RCT for HCC diagnosed 
according to the Milan criteria indicates the superiority of sur-
gical resection over RFA with respect to 3- and 5-year overall 
survival rates (p<0.001).264 Nevertheless, such results should be 
interpreted cautiously, as RFA is most effective for tumors <3 
cm. A meta-analysis of these three RCTs shows that the com-
plication rate was usually higher in the resection group than 
the RFA group (p=0.002) and that hospitalization duration was 
significantly longer in the resection group than the RFA group 
(p<0.001).265 Nevertheless, it is not possible to draw a definite 
conclusion about the overall or disease-free survival rate of 
HCC patients on the basis of a meta-analysis of the three RCTs 
mentioned above, because the indications differed substantially 
among studies.265 In contrast, RFA may be unfeasible because 
of the tumor location in some cases, making surgical resection 
more useful.263 As a strategy combining the advantages of these 
treatment modalities for small HCCs, i.e., the lower invasiveness 
of RFA and better curative potential of hepatic resection, primary 
RFA and subsequent resection in cases of failed RFA can be 
considered. A recent decision model analysis shows there was 
no difference in the survival outcomes of patients with single 
HCC smaller than 2 cm between the combined strategy and re-
section monotherapy.266
For intermediate-sized HCCs (i.e., 3–5 cm), the local recur-
rence rates after RFA are reported to range from 30% to 50%,252 
and combined treatment of TACE and RFA can be considered 
for these tumors. The difference in the 3-year overall survival 
rates between combined treatment and RFA monotherapy is 
<10% for tumors smaller than 3 cm267,268 but is much greater for 
HCCs 3–5 cm in diameter.268 Meta-analyses of RCTs also show 
similar results.269,270 
No RCT has compared re-resection and RFA for recurrent 
HCC following hepatic resection. However, a recent retrospective 
analysis shows that the 2- and 5-year overall survival rates after 
re-resection and RFA are 90% vs 96% and 72% vs 83%, respec-
tively; the differences are not statistically significant.271 Another 
retrospective study shows similar results.272 In those studies, 
baseline liver functional status might have been unfavorable in 
the RFA group compared to the surgical group. Consequently, 
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RFA appears comparable to re-resection for the treatment of 
recurrent HCC following hepatic resection, although further in-
vestigation is necessary to confirm this.273
2. Percutaneous ethanol injection
PEIT is widely used in the treatment of HCC because it is 
relatively convenient to perform and adverse reactions are in-
frequent. However, PEIT has been largely supplanted by RFA 
recently, mainly because PEIT should be performed repetitively 
in contrast to RFA and it is difficult to obtain complete necrosis 
for tumors larger than 3 cm. PEIT is now usually reserved for 
patients with ≤3 nodules ≤3 cm in diameter.
As a special consideration, PEIT can be performed to treat 
peri vascular tumors to reduce the heat sink effect of RFA. 
However, the risk of biliary stricture is not eliminated by PEIT 
if the tumors are located in the liver hilum.274 The reported 
rates of tumor necrosis after PEIT range between 66% and 
100%.249-251,259 In particular, the therapeutic efficacy of PEIT 
largely depends on the tumor size; the rate of tumor necrosis 
decreases with increasing tumor size. A rate of tumor necrosis 
≥90% is reported for tumors smaller than 2 cm, but the rate 
decreases to approximately 50% for 3–5-cm tumors. Local tu-
mor progression rates after PEIT range between 24% and 34%, 
although there is no consensus on the definition of local tumor 
progression.275-277 For Child-Pugh class A patients with solitary 
tumors smaller than 2 cm, the 3- and 5-year overall survival 
rates are 70%–80% and ≥50%, respectively. For tumors 2–3 cm 
in diameter, the 3-year overall survival rate ranges from 47% to 
64%.249,259
For cirrhotic patients with Child-Pugh class A or B and a 
solitary tumor smaller than 3 cm, several comparative studies 
show no definite differences in the survival outcomes between 
PEIT and surgical resection.278,279 In particular, an RCT compar-
ing PEIT and surgical resection targeting 76 patients who had 
one or two HCC nodules ≤3 cm reports no difference in the sur-
vival rates or local recurrence rates between treatment groups.279 
However, it is very difficult to reach a definite conclusion based 
on a single RCT. Furthermore, the sample size of that RCT was 
calculated on the basis of the tumor recurrence rate and not the 
survival rate. The 5-year survival rates differed greatly—46% 
and 81.8% in the PEIT and resection groups, respectively—
even though there was no significant difference in the overall 
survival rates of the two treatments. Therefore, additional well-
designed prospective controlled studies are necessary to reach a 
definite conclusion.
3. Other locoregional therapies 
Other local therapies are currently under investigation, in-
cluding microwave ablation, cryoablation, high-intensity fo-
cused ultrasound, laser ablation, and holmium injection therapy 
among others. An important advantage of microwave ablation 
over RFA is that treatment efficacy is less affected by vessels lo-
cated near the tumor. In addition, effective ablation can be ex-
pected even for tissues with low electrical conductivity, and the 
simultaneous application of multiple electrodes is technically 
feasible with this technique.280,281 Despite its potential advan-
tages, no RCT has compared microwave ablation and RFA with 
respect to clinical usefulness. 
Furthermore, no RCTs have evaluated the other ablation 
techniques mentioned above; even single-arm studies do not 
demonstrate any additional benefits over RFA with respect to 
response or survival outcomes. Therefore, clinical indications for 
these various ablation techniques are currently uncertain.
Recommendations (Table 2)
1. RFA provides survival comparable to that of resection in 
patients with single-nodular HCCs ≤3 cm in diameter (A2).
2. RFA is superior to PEIT in terms of anticancer effect and 
survival (A1). For HCCs ≤2 cm in diameter, PEIT can be consid-
ered if RFA is unfeasible, because the outcomes of both modali-
ties are similar (A2).
3. Survival outcomes can be improved by combining TACE 
and RFA compared to RFA alone in patients with tumors 3–5 
cm in diameter if resection is unfeasible (A2).
TACE AND OTHER TRANSARTERIAL THERAPIES
Most HCC patients are unresectable at the time of diagnosis 
because of portal hypertension, poor liver functional status, 
multiplicity of tumors, portal vein tumor invasion, inability to 
secure sufficient resection margin around the tumors, old age, 
and severe comorbidities.282 TACE is the most commonly used 
nonsurgical treatment modality for these patients; meanwhile, 
tumor necrosis can be achieved by the combined effects of 
antitumor chemotherapy and selective ischemia of tumor tis-
sue.13,282,283 TACE is the most widely practiced primary treatment 
modality for HCC in Asia and North America.284 TACE can be 
classified as conventional TACE using lipiodol and drug-eluting 
bead TACE (debTACE).285,286 It is important to note that TACE 
should be distinguished from transarterial embolization, which 
uses only embolic material, and HAIC, which uses only antitu-
mor chemotherapeutic agents.287,288 
1. Conventional TACE
The TACE procedure involves mixing chemotherapeutic 
agents such as doxorubin, cisplatin, and mitomycin with io-
dized oil and injecting the mixture into the feeding artery as an 
emulsion. This is followed by arterial embolization using gelatin 
sponge particles, polyvinyl alcohol particles, or microspheres, 
which induce selective tumor ischemia. The most important 
technique for maximizing the antitumor effect and minimiz-
ing liver toxicity when performing TACE is to superselect the 
feeding arteries of tumors as distal as possible.289 Regarding 
the repetition strategy of TACE, on-demand repetitions to treat 
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the residual or recurrent tumors can minimize the incidence of 
procedure-related liver toxicity, which is therefore preferable to 
on-schedule regular repetitions every 1–2 months. 
Several RCTs and meta-analyses confirm compared to sup-
portive treatments, TACE results in more favorable tumor re-
sponse, time to progression, and survival outcomes in patients 
with unresectable HCC.77,290,291 A recent prospective cohort study 
by the Japanese Liver Cancer Study Group reports that the 1-, 
3-, 5-, and 7-year survival rates of 8,510 patients who under-
went TACE were 82%, 47%, 26%, and 16%, respectively; for tu-
mors larger than 5 cm, the 1-, 3-, and 5-year survival rates were 
63%, 30%, and 16%, respectively.292 In a recent prospective 
multicenter study performed in 27 Japanese and South Korean 
centers, the complete or partial remission rate according to the 
modified Response Evaluation Criteria in Solid Tumors (mRE-
CIST) criteria was 73% and the 2-year overall survival rate was 
75%; these figures are higher than those previously reported in 
the literature.293 In that study, grade 3–4 severe toxicities after 
TACE included elevated serum alanine aminotransferase level 
in 36% of patients, thrombocytopenia in 12%, and abdominal 
pain in 4%, while mild fever occurred in 57%. In another ret-
rospective analysis, postembolization fever >38.0oC occurred 
after TACE in 20% of patients; it occurred more frequently in 
patients with tumors >5 cm and was a poor prognostic factor 
for survival.294 Even though TACE can be performed safely in 
general, severe complications such as irreversible hepatic failure 
occur in 3% of patients and postembolization syndrome, which 
is characterized by transient fever and abdominal pain, occurs 
more frequently, affecting 60%–80% of patients.295 The best tu-
mor response and the lowest complication rates after TACE can 
be expected for patients with favorable performance status, with 
nodular HCCs, and without traces of vascular invasion. Future 
RCTs should evaluate the survival benefits of TACE for patients 
with unfavorable prognostic factors such as poor performance 
status, major portal vein tumor invasion, Child-Pugh class C, 
and extrahepatic metastasis.
Local tumor response after TACE can vary substantially ac-
cording to the size and number of tumors as well as patterns of 
tumor growth, such as tumor encapsulation and vascular inva-
sion. The complete remission rate is quite low for large or mul-
tiple tumors despite multiple TACE sessions. However, in cases 
with small tumors, complete tumor necrosis can be obtained in 
more than 50% of cases after superselective TACE.296 For pa-
tients with Child-Pugh class A and surgically resectable HCC <4 
cm, the 5-year overall survival rate after subsegmental TACE is 
reported to exceed 50%.289,292 A prospective cohort study from 
Korea comparing surgical resection after primary TACE with 
TACE monotherapy published a decade ago reports that the 
survival rates were similar between the two treatment groups 
in cases in stage T3. In addition, the survival rate of the TACE 
group in stage T1 and T2 cases was similar to that of the surgi-
cal resection group if iodized oil was compactly retained within 
the tumor.297 In a recent prospective cohort study on BCLC stage 
A patients for whom resection or ablation could not be per-
formed, the 1-month complete remission rate according to the 
mRECIST criteria were 67% and the 3-year overall survival rate 
was 80%.298 In another recent retrospective study comparing 
resection, RFA, and TACE as initial treatments for single small 
HCC <3 cm in diameter, the unadjusted 5-year overall survival 
rate of the TACE group was the lowest at 74.2%. However, after 
adjusting for liver functional status, thrombocytopenia, varix, 
etc., the differences in the survival outcomes among the groups 
lost statistical significance.299 Taking the potential selection bias 
of the abovementioned studies into account, TACE can be con-
sidered an alternative treatment with curative intent if a patient 
rejects surgical treatment, is high risk for surgery, or is contra-
indicated for RFA.
Portal vein tumor invasion occurs in approximately 30% 
of HCC patients in Korea.13 According to the AASLD practice 
guidelines, systemic chemotherapy with sorafenib is the standard 
primary treatment for HCC invading the portal vein.57 However, 
in practice, this recommendation is not routinely followed by 
physicians, because the expected survival benefits are modest.284 
Therefore, further investigations of effective alternative treat-
ments are required. When TACE is performed for HCC patients 
with good hepatic functions but portal vein tumor invasion, the 
risk of hepatic functional deterioration after TACE is reported to 
be acceptably low.300-302 The 1- and 3-year overall survival rates 
of such patients after repeated TACE range from 25%–35% and 
9%–10%, respectively.292,303,304 In a prospective study target-
ing HCCs invading the major portal vein, the median survival 
period of the TACE-treated group (5.0 to 5.1 months) was 2 to 
2.5 months longer than those of the supportively treated group; 
however, the difference was not statistically significant probably 
because of the small number of patients included.291,302 However, 
a recent study from Korea reports that the median survival rate 
of TACE-treated HCC invading the major portal vein is 22 to 30 
months for a subgroup of patients with nodular tumor growth 
or limited tumor extent.302,303 A recent prospective nonrandom-
ized study on unresectable HCC patients with portal vein inva-
sion shows more favorable survival outcomes for the TACE-
treated group than the supportive treatment group.304 However, 
the lack of randomization in that study limits the validity of this 
finding. Therefore, additional well-designed RCTs are required to 
confirm the survival benefits of TACE over supportive treatment 
in HCC patients with portal vein invasion. Future investigations 
are also required to compare the clinical effectiveness of TACE 
monotherapy with other monotherapies (i.e., radiation therapy, 
systemic sorafenib, hepatic arterial infusion chemotherapy, etc.) 
and combined treatments of those therapies and TACE while 
considering liver functional status, tumor extent, and the extent 
of portal vein invasion.
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2. Drug-eluting bead TACE
Drug-eluting beads, which are microspheres loaded with high-
dose doxorubicin, represent a newly developed embolic agent 
for tumor feeders. The major theoretical advantage of debTACE 
is the higher intratumor drug concentration and lower serum 
drug concentration due to the slow release of doxorubicin from 
the microspheres after embolization of the tumor feeders. In 
prospective clinical trials, liver toxicities and systemic adverse 
effects occur less frequently after debTACE than conventional 
TACE.305,306 In contrast, a phase II RCT on 212 HCC patients 
demonstrates no additional benefit of debTACE over conven-
tional TACE with respect to 6-month complete or partial remis-
sion rate.305 However, subgroup analyses show that debTACE 
was superior to conventional TACE in patients with Child-Pugh 
class B, ECOG performance status 1, bilobar disease, or recurrent 
HCCs.305 In another RCT, there was no significant difference be-
tween the two treatments with respect to tumor response, time 
to progression, or survival period.307 The 5-year overall survival 
rates of HCC patients after debTACE and conventional TACE 
were 38.3% and 22.5%, respectively.308,309
When debTACE is performed by experienced interventional 
radiologists, postembolization syndrome or systemic adverse ef-
fects occur less frequently.306,310 However, there is a lack of evi-
dence confirming the long-term survival benefits of debTACE 
compared to conventional TACE, thus warranting further phase 
III RCTs.
3. Transarterial radioembolization
TARE involves the injection of implantable radioactive micro-
spheres into tumor-feeding arteries in order to expose the tumor 
to highly concentrated radiation while protecting the normal 
parenchyma. Yttrium-90 (90Y) is the most commonly used ra-
dioisotope and emits high-energy and pure β-rays with a half-
life of 64.2 hours, and mean and maximum tissue penetration 
of 2.5 and 11 mm, respectively. The microspheres available for 
90Y infusion are about 35 μm in diameter and are made of resin 
or glass. The small size of the injected microspheres and their 
concentration at the hypervascular HCC minimize the embolic 
effect on surrounding tissue. Preprocedural angiography and 
99mTc-labeled macroaggregated albumin scan are required to 
decide on the treatment site, determine the radiation dose, and 
detect and calculate the degree of shunting to the lungs and any 
other extrahepatic organs.
In a prospective single-arm phase II study of 52 patients with 
intermediate or advanced HCC treated with TARE, the objec-
tive tumor response rate (i.e., complete or partial remission rate) 
was 40.4%, and the median survival period was 15 months.311 
In another large retrospective cohort study, the median survival 
periods of patients with and without portal vein invasion were 
10 and 15.3 months, respectively; the difference was statistically 
significant. The median survival periods of patients with Child-
Pugh class A and B were 17.2 and 7.7 months, respectively; 
the difference was also statistically significant.312,313 In a recent 
prospective multicenter study performed in Korea on 40 HCC 
patients in BCLC stage B or C, the 3-month tumor response rate 
was 57.5% and the 3-year overall survival rate was 75%.314
The most frequent adverse effect after 90Y TARE is transient 
fatigue. However, postembolization syndrome is less likely to 
occur than in conventional TACE, because the embolic effect 
of 90Y TARE is not as strong. Therefore, 90Y TARE can be per-
formed safely for patients with portal vein tumor thrombosis. 
Elevated serum bilirubin levels occur in 20% of patients, and 
the mortality rate within 1 month ranges from 0% to 3%.311-313 
Severe complications such as radiation pneumonitis and gastro-
duodenal ulcer can occur in the event of inadvertent emboliza-
tion into the extrahepatic organs. Therefore, 90Y TARE requires 
meticulous precautions and experience performing radioemboli-
zation.
In summary, no RCT has compared 90Y TARE with other stan-
dard treatments with respect to long-term survival outcomes 
and complication rates. Therefore, it is difficult to suggest indi-
cations for 90Y TARE in HCC patients. However, the incidence of 
postembolization syndrome and systemic adverse effects with 
90Y TARE are relative low, and the tumor response rates are 
similar to those of conventional TACE. Accordingly, a phase III 
RCT is required to determine the indications, cost-effectiveness, 
and survival outcomes for this new type of treatment.
Recommendations (Table 2)
1. TACE is recommended for patients with good performance 
status without major vascular invasion or extrahepatic spread 
who are ineligible for surgical resection, liver transplantation, 
RFA, or PEIT (A1).
2. TACE should be performed through tumor-feeding vessels 
using selective/superselective techniques to maximize antitumor 
activity and minimize hepatic damage (B1).
3. Chemoembolization using drug-eluting beads results in 
less systemic adverse events and has similar therapeutic efficacy 
compared with conventional TACE (B2).
4. In case of portal vein invasion, TACE can be considered for 
patients with localized tumors and well-preserved liver function 
(B2).
EXTERNAL-BEAM RADIATION THERAPY
External-beam radiation therapy (EBRT) for the treatment of 
HCC is commonly used for lesions that are surgically unresect-
able and not amendable with other local modalities. Child-Pugh 
class A or upper B are criteria for EBRT. The reported overall 
response rates and median survival after EBRT are 40%–90% 
and 10–25 months, respectively.315 EBRT requires computerized 
radiation therapy planning by CT, and the liver volume receiv-
ing ≥30 Gy must be limited to ≤60% of the total liver volume in 
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three-dimensional radiotherapy planning-based dose–volume 
analysis.316 For hypofractionated EBRT consisting of ≤10 frac-
tions, the normal liver volume receiving <15 Gy must be ≥700 
mL317 and the dose to the normal liver volume excluding the tu-
mor must be limited to ≤28 Gy (corrected to 2 Gy per fraction-
equivalent dose).318
EBRT can be used for patients with HCC who are unsuitable 
for surgical resection, LT, RFA, PEIT, or TACE. In most centers, 
hypofractionated radiotherapy including stereotactic ablative 
radiation therapy is used to treat patients with Child-Pugh A 
or superb B liver function and adequate normal liver volume; 
the 2-year local control and survival rates are reported to range 
from 70% to 100% and 50% to 75%, respectively.319-325 In 
particular, stereotactic ablative radiation therapy for the treat-
ment of ≤3 lesions and lesions with a cumulative diameter ≤6 
cm results in local control rates exceeding 90%.319,323-325 Proton 
therapy for HCC results in a 2-year local control rate from 75% 
to 96% and a 5-year survival rate from 23% to 44%.199,326-329
An advantage of EBRT is that it can be performed safely 
regardless of the presence of portal vein invasion by the tu-
mor.330-344 One study reports that when EBRT was used for 
patients unsuitable for TACE owing to severe tumor-induced ar-
teriovenous shunts, 20% of these patients were able to undergo 
TACE successfully after radiation therapy-induced vascular 
occlusion.345 A meta-analysis reports that the use of TACE in 
combination with EBRT improves the 3-year survival rate by 
10%–28% compared to TACE monotherapy.346 Meanwhile, the 
results of controlled studies comparing combination treatments 
are anticipated. Moreover, the addition of EBRT for HCC after 
incomplete TACE is reported to result in a complete response 
rate of 20.9%.347 In a Korean multicenter retrospective cohort 
analysis, 78.4% of patients received TACE before receiving 
EBRT.348 Another recent study shows that TACE combined with 
EBRT for resectable HCC with portal vein invasion resulted in 
a superior median survival of 12.3 months versus 10.0 months 
for the surgical group.349 Furthermore, combined treatment for 
HCC patients with inferior vena cava invasion also resulted in a 
superior median survival period of 11.7 months in comparison 
with the historical cohort who received TACE alone.350 The se-
quential combination of EBRT 2 weeks after TACE may be com-
plicated by liver dysfunction; however, Common Terminology 
Criteria of Adverse Events grade ≥3 liver dysfunction is reported 
in only 2.5% of all patients.351
In one study, regional chemotherapy with 5-fluorouracil and 
cisplatin combined with EBRT for locally advanced HCC re-
sulted in a 3-year survival rate of 24.1% and a median survival 
period of 13.1 months.352 The same institution reports a median 
progression-free survival of 4.5 months and overall survival of 
9.8 months after TACE followed by EBRT and concurrent intra-
arterial 5-fluorouracil for locally advanced HCC with portal 
vein invasion and intrahepatic metastases.353 In another study, 
the addition of EBRT to intra-arterial 5-fluorouracil and sub-
cutaneous interferon treatment for 40 patients with advanced 
HCC and portal vein invasion significantly improved the time 
to progression from 4.0 to 6.9 months and the median survival 
from 9.1 to 12.0 months.354 EBRT can also be considered a local 
neoadjuvant treatment for large HCCs with the aim of improv-
ing resectability. Accordingly, it has been reported that surgery 
can be performed safely post-EBRT, resulting in an effective 
response to neoadjuvant radiotherapy.355 In addition, EBRT can 
be considered a bridging treatment for patients awaiting liver 
transplantation.199,200,319 Nevertheless, a controlled prospective 
comparative study is required to establish the role of EBRT as 
a new adjuvant treatment. EBRT can also be used as a second-
line treatment for recurrent HCC after various nonsurgical treat-
ments including TACE.348,356,357 
EBRT is also effective for relieving symptoms such as can-
cer pain.315,358 In patients with jaundice presenting with biliary 
obstructions due to the progression of HCC, EBRT has been 
demonstrated to successfully reduce tumor size and relieve 
symptoms; accordingly, EBRT is also expected to improve the 
survival in these patients.359,360 In HCC patients with abdominal 
lymph node metastases, EBRT results in response rates of ap-
proximately 80%361-364 with improved median survival time.365 
In HCC patients with symptomatic bone metastases, EBRT is 
reported to relieve pain in 75%–99% of patients366-370 as well as 
symptoms in patients with brain metastases from HCC.371 More-
over, in a previous study, EBRT doses from 30 to 50.7 Gy for 
spinal cord compression from vertebral metastases resulted in 
ambulatory rates of 85% and 63% at 3 and 6 months, respec-
tively.372 In two other studies, EBRT for lung metastases resulted 
in response rates from 60% to 70% while symptom relief was 
observed in 90% of symptomatic patients.361,373
Recommendations (Table 2)
1. EBRT can be performed in HCC patients if liver functions 
are Child-Pugh class A or superb B and the irradiated total liver 
volume receiving ≥30 Gy is ≤60% (B1). 
2. EBRT can be considered for HCC patients ineligible for sur-
gical resection, liver transplantation, RFA, PEIT, or TACE (C1).
3. EBRT can be considered for HCC patients who show in-
complete response to TACE when the dose–volume criteria in 
Recommendation 1 are met (B2).
4. EBRT can be considered for HCC patients with portal vein 
invasion when the dose–volume criteria in Recommendation 1 
are met (C1).
5. EBRT is performed to alleviate symptoms caused by pri-
mary HCC or its metastases (B1).
SYSTEMIC THERAPIES
1. Sorafenib
Sorafenib is a multi-tyrosine kinase inhibitor targeting vas-
cular endothelial growth factor receptor 2, platelet-derived 
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growth factor receptor, Raf-1, and c-kit. Sorafenib was the first 
approved molecular targeted agent for the treatment of HCC. In 
the SHARP study, a global phase III trial, the median survival 
of HCC patients with portal vein tumor invasion or extrahepatic 
metastasis treated with sorafenib was 10.7 months, which was 
significantly longer than 7.9 months in patients who received 
placebo (HR, 0.69; 95% CI, 0.55 to 0.87; p=0.00058).374 The time 
to progression in the sorafenib group was 5.5 months, which 
was also significantly longer than 2.8 months in the control 
group.374 In an Asia-Pacific phase III trial that included Korean 
patients with unresectable HCC, patients who received sorafenib 
had a significantly longer median survival (6.5 months) than 
that of the control group (4.2 months; HR, 0.68; 95% CI, 0.50 to 
0.93; p=0.014).375 The median survival of patients treated with 
sorafenib was consistently reported to be approximately 10 
months in the following 3 randomized controlled phase III trials 
testing novel molecular targeted agent in which sorafenib treat-
ment was the control group.376-378 On the basis of the results of 
clinical trials, sorafenib is currently the only molecular targeted 
agent proven to prolong survival in advanced HCC patients.
The abovementioned two phase III trials for sorafenib (i.e., 
the SHARP and Asia-Pacific trials) recruited HCC patients with 
Child-Pugh class A and ECOG performance status 0–2. In clini-
cal practice, the safety and efficacy of sorafenib are reported to 
be comparable between Child-Pugh class A and B patients;379-382 
however, the prognosis is reported to differ with respect to the 
presence of ascites and Child-Pugh score.383 Thus, although 
sorafenib can be used cautiously in patients with decreased liver 
function, more controlled studies are necessary. The most com-
mon adverse event related to sorafenib treatment is hand–foot 
syndrome reaction (HFSR), followed by fatigue, skin rash, an-
orexia, weight loss, hypertension, and alopecia. As HFSR tends 
to be decreasing sptontaneously after 3 months of treatment, 
it is important to continue therapy through patient education 
and proper management; for example, creams containing urea 
may be helpful for preventing dryness of the hands and feet. 
Furthermore, it is recommended to remove thick calluses, wear 
comfortable shoes with cushioning, avoid hot water, and take 
analgesics if necessary.384 Sorafenib is primarily used in ad-
vanced HCC patients with vascular invasion (i.e., the portal vein, 
hepatic vein, or inferior vena cava) or extrahepatic metastasis. 
It can also be used in HCC patients in whom locoregional thera-
pies have failed or are not indicated. Although there is no clear 
definition of TACE failure or refractoriness, if HCC progresses 
and the tumor stage advances despite repeated applications of 
TACE (i.e., 3 times within 6 months) for residual or recurrent 
tumors after the initial TACE, sorafenib might be indicated on 
the basis of the concept of TACE failure or refractoriness.385-387 
Regarding combination therapy with TACE and sorafenib in 
intermediate-stage HCC, a single-center phase II study shows 
longer survival and time to progression in combination therapy 
than a historic control group treated with TACE monotherapy;388 
while another phase II study, the SPACE trial, does not show 
the beneficial outcomes of combination therapy;389 the former 
has the limitation of being a single-arm study, while the latter 
has drawbacks of study design, specifically not “on-demand” 
TACE but “scheduled” TACE and an endpoint of overall survival 
in patients with intermediate-stage HCC, who are expected to 
have favorable long-term prognosis. On the basis of the proven 
safety of combination therapies in both of these trials, there is 
an ongoing phase III trial of combination therapy with TACE 
and sorafenib in advanced HCC. 
Recommendations (Table 2)
1. Sorafenib is indicated for HCC patients with very well-
preserved liver function (i.e., Child-Pugh class A), good perfor-
mance status, and regional lymph node or extrahepatic spread 
or patients with tumor progression on other therapies (A1).
2. Sorafenib is recommended for HCC patients with very well-
preserved liver function (i.e., Child-Pugh class A), and good 
performance status, and vascular invasion (A2).
3. Sorafenib is considered for HCC patients with preserved 
liver function (i.e., Child-Pugh class superb B) and good perfor-
mance status if the above conditions (1 and 2) are satisfied (B1).
2. Cytotoxic chemotherapy
Sorafenib is recommended as a first-line systemic agent; 
however, despite several clinical trials, no second-line agent is 
proven to be effective in cases in which sorafenib fails or intol-
erance. Cytotoxic chemotherapy can be considered in cases of 
HCC progression on sorafenib or drug intolerance.390-392 Most 
cytotoxic chemotherapeutics have shown poor response and 
no survival benefit through RCTs. Even though some agents 
result in a relatively good antitumor response, it is unrealistic to 
perform a multicenter prospective RCT evaluating efficacy and 
safety because of lack of study funding/sponsership. 
Despite the widespread use of doxorubicin, the response 
rate is less than 20%.393-395 Satisfactory results have not been 
obtained with single agents such as 5-fluorouracil,396 gem-
citabine,397,398 oxaliplatin,399 capecitabine,400 and irinotecan.401 
In addition, octreotide,402,403 interferon,404 and tamoxifen405 have 
not shown any survival benefit for HCC.
Several combination regimens have been tried because of the 
modest efficacy of monotherapy. The PIAF regimen (cisplatin/
interferon a-2b/doxorubicin/fluorouracil) shows better objective 
response rates (20.9% vs 10.5%, p=0.058) and median over-
all survival (8.67 months vs 6.83 months; RR, 0.97; p=0.830), 
although the difference failed to reach statistical significance. 
Meanwhile, hematologic toxicities were significantly more 
frequent in PIAF group.406 Another combination regimen, 
FOLFOX (oxaliplatin/fluorouracil/leucovorin) was compared 
with doxorubicin monotherapy. Patients receiving FOLFOX 
had significantly better progression-free survival (2.93 months 
vs 1.77 months, p<0.01) and disease control rate (52.17% vs 
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31.55%, p<0.001) but a nonsignificant trend toward better sur-
vival (6.4 months vs 4.97 months, p=0.07).407 Some results of 
cisplatin-containing regimens (e.g., in combination with doxo-
rubicin,408 capecitabine,409,410 or 5-fluorouracil411) or oxaliplatin-
containing regimens (e.g., in combination with gemcitabine412 
or capecitabine413) for HCC have been reported, but the benefits 
of these regimens compared to monotherapy are still lacking.
Most patients with HCC are accompanied by chronic liver 
disease or liver cirrhosis, which can alter the metabolism of 
chemotherapeutics and increase their toxicity.414 Therefore, sys-
temic chemotherapy should be reserved for patients with good 
performance status and liver function. In addition, great care 
is required to maintain the quality of life of patients receiving 
chemotherapeutics.
3. Hepatic arterial infusion chemotherapy
HAIC can directly deliver high concentrations of chemothera-
peutic agents via the hepatic artery with low systemic toxicities. 
HAIC is usually performed for HCC with portal vein invasion 
and can be considered for TACE-refractory cases. Recent reports 
demonstrate that HAIC can also be tried for sorafenib-refractory 
or intolerant HCCs, although further studies are warranted.415,416 
The most widely used agent in HAIC is 5-fluorouracil, which is 
either administered alone or with cisplatin, showing response 
rates from 3.8% to 38.5% and median survival from 5 to 19.5 
months.417-420 HAIC can be administered in combination with 
systemic interferon.421,422 The implantable device required for 
HAIC can sometimes cause complications such as infection and 
occlusion. Nevertheless, further studies are warranted, because 
there is insufficient evidence demonstrating that HAIC improves 
survival compared to systemic chemotherapy or best supportive 
care.
Recommendations (Table 2)
1. Cytotoxic chemotherapy can be considered for HCC pa-
tients with advanced tumors who have well-preserved liver 
function and good performance status in whom sorafenib ther-
apy has failed (C1).
ADJUVANT THERAPY
Adjuvant therapy usually refers to an additional treatment 
after definitive or curative therapy to prevent recurrence. As 
there recurrence rate 5 years after curative resection for HCC is 
very high at 70% (see “Liver Resection” section),142,423,424 an ef-
fective adjuvant therapy is urgently required. There is currently 
no proven modality;58 neither sorafenib nor cytotoxic chemo-
therapy is recommended as an adjuvant therapy. Furthermore, 
there is no evidence that TACE prevents HCC recurrence after 
curative resection.425 
Although one study reports that 131I infusion via the hepatic 
artery after curative resection reduces the recurrence of HCC, 
no validation study was performed.426,427 Thus, this radionuclide 
therapy is not recommended at present. A study of activated 
immune cells derived from patients shows a 15% decrease in the 
3-year recurrence rate compared to that of the control group.428 
However, there has been no reliable study to corroborate this.
TACE can result in the downstaging of HCC, enabling cura-
tive resection. Even for resectable HCC, TACE can be applied 
prior to resection as a neoadjuvant therapy. However, there is 
no evidence that TACE followed by resection increases disease-
free survival compared with resection only in resectable HCC.429 
Recommendations (Table 2)
1. Adjuvant TACE, sorafenib, and cytotoxic chemotherapy are 
not recommended for HCC patients treated with curative resec-
tion (B1).
PREEMPTIVE ANTIVIRAL TREATMENT
1. HBV carriers
The rate of HBV reactivation in HCC patients after cytotoxic 
chemotherapy varies widely from 30% to 60%,430,431 and the 
subsequent mortality rate is reported to be approximately 30% 
of all deaths resulting from HBV reactivation. HBV reactivation 
with concomitant elevation of serum HBV DNA level or abnor-
mality of biochemical liver function is observed in 20%–50% 
of total HBV carriers who receive immunosuppressants or cy-
totoxic chemotherapy for the treatment of malignancies other 
than HCC (e.g., breast cancer, hematologic malignancies, and 
other solid cancers).430,432-435 Therefore, the test for hepatitis B 
surface antigen (HBsAg) must be performed in patients at high 
risk for HBV infection prior to immunosuppressive therapy or 
cytotoxic chemotherapy.436 Antiviral drugs should be preemp-
tively administered in HBV carriers at the onset of the cytotoxic 
chemotherapy or immunosuppressant administration and must 
be continued for at least 6 months. Although further research is 
required to clarify the adequate serum HBV DNA level, recur-
rence is more likely after the discontinuation of antiviral drugs 
in patients with high HBV DNA levels prior to cytotoxic che-
motherapy. Therefore, in patients with HBV DNA levels >2,000 
IU/mL prior to cytotoxic chemotherapy, continuation of anti-
viral treatment should be considered until the treatment goal 
of chronic hepatitis B is reached.436 Most studies on preemptive 
antiviral treatment are limited to lamivudine, but other recently 
developed antiviral drugs can be used. In cases of lamivudine 
resistance, antiviral drugs should be replaced according to the 
treatment guidelines for resistance.437,438 In cases in which anti-
viral therapy is expected to continue for more than 12 months 
in particular, the antiviral drug with the minimum resistance 
profile should be selected.439,440 Interferon is not recommended 
as a preemptive treatment because of the risk of bone mar-
row suppression and transient aggravation of hepatitis. In the 
HBsAg-negative, anti-HBc–positive, and anti-HBs–positive 
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patients, HBV reactivation can develop very rarely, and there is 
little evidence to recommend uniform preemptive treatment ow-
ing to a lack of research.436
Comparatively many studies have evaluated HBV reactiva-
tion during TACE for the treatment of HCC; HBV reactivation 
is reported to occur in 4%–40% of patients.430,441-445 According 
to a study comparing preemptive lamivudine treatment to a 
nonadministered control group during TACE,444 significant dif-
ferences were observed with respect to HBV reactivation (2.8% 
and 40.5%) as well as the consequent occurrence of hepatitis 
(2.8% and 19.7%) and liver failure (0% and 8.1%). Hence, pre-
emptive antiviral treatment can be considered for HBV-positive 
HCC patients undergoing TACE. However, differences in che-
motherapeutic agents, and treatment interval and frequency 
may have resulted in discordant HBV reactivation rates.444-446 
Therefore, additional research is required to determine the serum 
HBV DNA levels and biochemical liver function test levels that 
require preemptive antiviral treatment.
HBV reactivation rates after HAIC for HCC (24%–67%) are 
reported to be higher than those after TACE possibly because 
of the higher dose of chemotherapeutic agents, as HAIC is car-
ried out in shorter intervals.431,447,448 However, more research is 
needed to support the claim that HAIC has a higher reactivation 
rate than TACE, as only a few studies with a limited number 
of subjects have been reported and no comparative study with 
TACE has been performed.
Following the surgical resection of HCC, HBV reactivation 
with concomitant elevation in the HBV DNA level or abnormal 
biochemical liver function test is observed in 14%–32% of pa-
tients.449 In a prospective study comparing preemptive telbivu-
dine administration to a nonadministered control group from 
the day of resection, the HBV reactivation rates were 2.5% and 
31.8%, respectively. While 57.1% of the control group showed 
HBV reactivation within 1 week following surgical resection, 
only 2.5% of the telbivudine-administered group showed reacti-
vation within 4 weeks.439 The authors of that study recommend 
preemptive antiviral treatment before the surgical resection of 
HCC; however, that study involved only few patients at a single 
institution in China. Therefore, a large-scale multicenter study 
should be performed to determine a universal preemptive anti-
viral treatment before the surgical resection of HCC.
A study comparing preemptive lamivudine administration 
and a nonadministered control group following radiotherapy for 
HCC reports the HBV reactivation rates to be 0% and 21.8%, re-
spectively; meanwhile, alanine transaminase elevation occurred 
in 2.3% and 12.5% of patients, respectively.450 Another recent 
report suggests concurrent TACE and external radiotherapy may 
double the HBV reactivation rate compared to TACE alone.446 
However, it is difficult to recommend preemptive antiviral treat-
ment before external radiotherapy for HCC because of the lack 
of controlled prospective studies.
There are limited studies regarding HBV reactivation from 
PEIT or RFA; nonetheless, the HBV reactivation rates for these 
therapies are reported to be 0% and 5.6%–9.1%, respectively.451,452 
Meanwhile, no HBV reactivation was observed after sorafenib 
administration in a retrospective study.380 Regardless, more ob-
servations and research are required.
2. HCV carriers
Regarding HCV-related HCC, there are almost no reported 
cases of HCV reactivation or aggravation of hepatitis after HCC 
treatment. In a recent retrospective study on hepatitis virus re-
activation comparing HCV- and HBV-related HCC after TACE, 
the rates of HCV and HBV reactivation, hepatitis, and liver 
failure were 26.5% and 32.5%, 10.2% and 34.8%, and 0% and 
10.9%, respectively.453 No significant difference was observed 
between the HCV and HBV groups with respect to the reactiva-
tion rate, but the development of hepatitis and liver failure were 
significantly lower in the HCV-related HCC group. Hepatitis C 
treatments can be considered in patients with active chronic 
hepatitis C and completely eradicated HCC. As interferon and 
ribavirin administration may cause bone marrow suppression 
and transient aggravation of hepatitis, they are not recommend-
ed as preemptive treatments before cytotoxic chemotherapy in 
HCC patients.
Recommendations (Table 2)
1. Patients should be tested for hepatitis B surface antigen 
before starting cytotoxic chemotherapy or immunosuppressive 
therapy (A1).
2. Preemptive antiviral therapy is recommended for HBV car-
riers undergoing cytotoxic chemotherapy to prevent reactiva-
tion (A1). Preemptive antiviral therapy is considered for HBV 
infected patients receiving TACE (B1), hepatic arterial infusion 
chemotherapy (C1), surgical resection (C1), or EBRT (C1) to pre-
vent reactivation.
3. Antiviral treatment for HBV reactivation should follow the 
recommendations of the current KASL guidelines (A1). 
DRUG TREATMENT FOR CANCER PAIN IN HCC
Pain is one of the most troublesome symptoms in cancer 
patients. The prevalence of pain in cancer patients ranges from 
45% to 53%,454-456 and early aggressive palliative care includ-
ing pain management could improve survival in lung cancer 
patients.457 A few studies have investigated the prevalence of 
pain in HCC patients, which is reported to range from 22% to 
66.8%.455,458,459 Therefore, pain management should be consid-
ered an important aspect of palliative care for HCC patients. 
As most HCC patients have chronic liver disease and/or liver 
cirrhosis, their drug metabolism may be altered according to 
the degree of liver dysfunction.460 Furthermore, HCC patients 
receiving analgesics may suffer from more frequent and severe 
side effects. However, there is a paucity of studies on pain man-
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agement for patients with HCC and liver disease.461 Therefore, 
drug treatment for cancer pain in HCC patients should generally 
follow the principles of pain management for general solid tu-
mors.462-464 However, drug selection, dosage, and administration 
interval might need to be adjusted according to the degree of 
liver function impairment.
The universal strategy for cancer pain treatment is based on 
a sequential three-step analgesics ladder approach from nono-
pioids to weak opioids and finally to strong opioids according 
to pain intensity and the efficacy of pain control.462-464 The main 
nonopioid analgesics such as acetaminophen and nonsteroidal 
anti-inflammatory drugs (NSAIDs) are indicated for the treat-
ment of mild pain (numerical rating scale, 1–3). Meanwhile, 
weak opioids such as codeine, hydrocodone, and tramadol are 
indicated for mild to moderate pain (numerical rating scale, 4–6). 
Finally, strong opioids such as morphine, oxycodone, hydro-
morphone, fentanyl, and their analogues are the mainstay of 
analgesics for treating moderate to severe cancer-related pain 
(numerical rating scale, 7–10).
Acetaminophen is the most common cause of fulminant 
hepatic failure,465,466 but clinically significant hepatic injury is 
very rare when the dosage is limited to 4 g/day.467 Although one 
case report demonstrates that even therapeutic doses of acet-
aminophen less than 4 g/day in alcoholic patients without liver 
cirrhosis can result in acute liver failure,468 other studies show 4 
g/day in alcoholic patients is not associated with a significant 
increase in liver toxicity.469,470 Moreover, one study shows a 
significant increase in the liver enzymes of alcoholic patients 
taking acetaminophen 4 g/day.471 In patients with cirrhosis, 
acetaminophen 2–3 g/day is not associated with acute hepatic 
decompensation.472 Even though the half-life of oral acetamino-
phen is twice as long in patients with cirrhosis compared to 
healthy controls,473 significant hepatic injury is rare in patients 
with liver disease and/or cirrhosis at a dosage of less than 4 g/
day.473,474 Nonetheless, most experts recommend lowering the 
dosage of acetaminophen to 2–3 g/day in patients with liver 
cirrhosis because of the inevitable possibility of altered drug 
metabolism and increased half-life.475,476
The unbound drug concentrations of NSAIDs are generally 
elevated in liver disease patients, which can lead to more severe 
side effects and toxicity.477 Indeed, roughly 10% of total drug-
induced hepatotoxicity cases are related to NSAIDs,478 and 
NSAID-induced liver injury is well documents.466,479 Moreover, 
NSAIDs can cause nephrotoxicity,480 gastric ulcer, hemor-
rhage,481,482 decompensation of liver function, etc.472
As the liver is the major site of metabolism for most opioids, 
impaired metabolism and excretion of opioids due to underly-
ing liver disease in HCC patients can lead to increased side ef-
fects. Moreover, opioids are a well-known major precipitants of 
hepatic encephalopathy.474 Therefore, careful selection, and dos-
age and interval adjustment of drugs are required according to 
the liver metabolism of each opioid.476,483 Morphine is an active 
analgesic compound by itself, and more than 90% of metabo-
lites are excreted renally after glucuronidation in the liver. The 
half-life of morphine is approximately twice as long in cirrhotic 
patients as that in healthy controls.484,485 Furthermore, its bio-
availability is 4-fold greater in patients with HCC (68%) as that 
in healthy controls (17%).486 As the analgesic effect of codeine is 
presumed to be secondary following its conversion to morphine, 
serum levels are not expected. The ceiling effect of codeine may 
cause side effects before achieving a sufficient analgesic effect. 
Similarly, hydrocodone is metabolized to hydromorphone before 
producing an analgesic effect, which results in variable serum 
levels. Meanwhile, tramadol has 10-fold less affinity for opioid 
receptors than codeine and exerts its analgesic effect via the pe-
ripheral pain pathway, which may result in fewer side effects in 
patients with liver disease. However, its elimination half-life is up 
to 3-fold greater in patients with primary liver carcinoma than 
that in controls.487 Oxycodone is converted to various metabo-
lites including oxymorphone (an active metabolite), which may 
result in variable serum levels of metabolites and an unpredict-
able analgesic effect. The elimination half-life of oxycodone is 
prolonged, while its clearance is diminished with significant ven-
tilation depression in pretransplantation liver cirrhosis patients 
compared to posttransplantation patients.488 Hydromorphone is 
an active analgesic compound by itself and is metabolized and 
excreted after glucuronidation. Liver dysfunction does not have 
a relatively substantial effect on hydromorphone; the half-life 
of hydromorphone does not differ significantly in patients with 
moderate hepatic impairment compared to controls.489 Although 
fentanyl is metabolized by cytochrome, its metabolism does 
not yield toxic metabolites, significantly alter serum levels in 
cirrhotic patients.490 Furthermore, it is not influenced by renal 
dysfunction.476,483
Recommendations (Table 2)
1. Careful consideration is required for pain management 
with medication in patients with HCC and underlying liver dis-
ease. The dosage and dosing intervals of analgesics should be 
determined on the basis of liver functions (C1). 
2. In patients with HCC and chronic liver disease, the dosage 
of acetaminophen should be lowered (C1) and NSAIDs should 
be used with caution (B1). 
3. In patients with HCC and chronic liver disease, opioid anal-
gesics and their dosage should be selected carefully on the basis 
of drug metabolism and liver function (C1).
ASSESSMENT OF TUMOR RESPONSE AND POSTTREAT-
MENT FOLLOW-UP
1. Tumor response
The main endpoint in cancer research is overall survival. 
Nonetheless, tumor response and time to progression are also 
considered pivotal for the surrogate assessment of efficacy. In 
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oncology, tumor response was initially measured according 
to the 1979 World Health Organization (WHO) criteria as fol-
lows:491
(1) Complete response (CR): Complete disappearance of all 
known disease and no new lesions determined by two observa-
tions not less than 4 weeks apart.
(2) Partial response (PR): 50% reduction in total tumor load of 
all measurable lesions determined by two observations not less 
than 4 weeks apart.
(3) Progressive disease (PD): 25% increase in the size of one 
or more measurable lesions or the appearance of new lesions.
(4) Stable disease (SD): Cases not belonging to CR, PR, or PD.
However, several problems arose when applying these defini-
tions to clinical practice. For example, there were discrepancies 
in the criteria for measuring tumor size among researchers. Fur-
thermore, some researchers define progressive disease on the ba-
sis of the change in the size of one tumor, while others define it 
on the basis of the sum of the changes in the sizes of all tumors. 
Another limitation of the WHO criteria is properly reflecting the 
changes in tumor volume determined by recent advanced CT 
and MRI technologies. In order to overcome these problems, the 
Response Evaluation Criteria in Solid Tumors (RECIST) criteria 
and RECIST version 1.1 were developed and released in 2000 
and 2009, respectively. In these criteria, overall responses are 
determined after evaluating the treatment responses for all le-
sions that are targeted or nontargeted.492,493 The criteria used to 
determine objective tumor responses for targeted lesions (or an 
index lesion) are as follows:
(1) Complete response (CR): Disappearance of all targeted 
lesions. Any pathologic lymph nodes must have reduction in 
short axis to <10 mm. 
(2) Partial response (PR): At least a 30% decrease in the sum 
of the diameters of target lesions with respect to baseline sum 
diameter.
(3) Progressive disease (PD): At least a 20% increase in the 
sum of the diameter of the target lesion. In addition to the rela-
tive increase of 20%, the sum must also demonstrate an abso-
lute increase of at least 5 mm.
(4) Stable disease: Cases not belonging to CR, PR, or PD.
Meanwhile, the criteria for the evaluation of nontargeted le-
sions are as follows:492,494 
(1) Complete response: Disappearance of all nontargeted le-
sions and normalization of tumor marker levels. All lymph 
nodes must be nonpathologic in size (i.e., <10 mm short axis).
(2) Noncomplete response/nonprogressive disease: Persistence 
of one or more on-target lesions and/or maintenance of tumor 
marker levels above the normal limits.
(3) Progressive disease: Progression of existing nontargeted 
lesions or appearance of new lesions.
However, these criteria were primarily designed to evaluate 
cytotoxic agents. Therefore, they do not address measures of an-
titumor activity besides tumor shrinkage; thus, the best response 
in these criteria might be stable disease. As acknowledged in 
the original RECIST publication, assessments based solely on 
changes in tumor size can be misleading when applied to other 
anticancer drugs such as molecular targeted therapies or other 
therapeutic interventions.492 Therefore, these determinations may 
be inaccurate. Several clinical studies on HCC demonstrate that 
the RECIST criteria do not mirror the extent of tumor necrosis 
induced by interventional therapies or new molecular targeted 
drugs.374,495 In theory, viable tumor formation should be assessed 
by CT or MRI studies, and tumor viability should be defined 
according to the uptake of contrast agent in the arterial phase 
of dynamic imaging studies. In fact, extensive tumor necrosis, 
which develops after local treatment, may not be paralleled by a 
decrease in lesion diameter.374,495 To overcome these limitations, 
the EASL developed new criteria for HCC treatment response 
that take into account the degree of necrosis.496 Furthermore, 
mRECIST criteria were first proposed by a panel of experts;497,498 
this proposal is based on the fact that the diameter of the target 
lesions with viable tumors should guide all assessments. Specific 
modifications to the original criteria regarding the assessment 
of vascular invasion, lymph nodes, ascites, pleural effusion, and 
new lesions are summarized in Table 7. However, a limitation 
that should be noted is that the assessment of response to treat-
ment based on the mRECIST criteria can be influenced by the 
image quality of CT/MRI as well as the subjective decisions of 
radiologists. Because there is no solid evidence indicating which 
set of criteria is superior, the panel of experts recommends de-
termining whether a set of criteria outperforms the conventional 
RECIST criteria as well as correlations with pathologic studies 
and outcome prediction.
Recommendations (Table 2)
1. Assessment of response should follow both the RECIST and 
mRECIST criteria (B1).
2. Follow-up after complete response
Follow-up data after complete response in HCC are very lim-
ited. In cases of complete response after hepatic resection, trans-
plantation, or percutaneous local ablation, follow-up intervals 
are determined on the basis of pretreatment risk factors and the 
treatment-specific risk of recurrence.
 The 5-year recurrence rate following hepatic resection is 
up to 70% and is due to intrahepatic metastases and/or de 
novo carcinogenesis.96,423,499,500 Postoperative recurrence is usu-
ally classified as early (i.e., <2 years postoperatively) or late 
(i.e., >2 years postoperatively).142,497 Risk factors for recurrence 
are related to the tumor or underlying chronic liver disease. 
Tumor-related risk factors for recurrence are associated with 
early recurrence and include tumor size and number, degree of 
differentiation, vascular invasion, serum AFP (if elevated pre-
operatively), insufficient resection margin, and nonanatomical 
resection.142,146,499-502 Meanwhile, late recurrence risk factors are 
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related to underlying liver disease and include elevated serum 
HBV DNA during the perioperative period in cases of chronic 
hepatitis B,148,503-505 and persistent active inflammation and ad-
vanced degree of fibrosis in cases of chronic hepatitis C.506,507
The 5-year survival rate of liver transplantation exceeds 70% 
and the recurrence rate is less than 15% in patients meeting Mi-
lan criteria.163 Major risk factors for recurrence after transplanta-
tion are tumor size and vascular invasion; other risk factors in-
clude tumor number, degree of differentiation, serum AFP level, 
and bilobar location of tumors.508-510 Recurrence occurs in more 
than 90% of patients within 2 years, 35% of which occur in the 
liver if the abovementioned risk factors are present. A recent 
Table 7. Assessment of Tumor Response*
RECIST mRECIST
Target lesion response
    CR Disappearance of all target lesions Disappearance of any intratumor arterial enhancement 
in all target lesions
    PR At least a 30% decrease in the sum of the diameters of 
target lesions, taking the baseline sum of the diam-
eters of target lesions as a reference
At least a 30% decrease in the sum of the diameters 
of viable (enhancement in the arterial phase) target 
lesions, taking the baseline sum of the diameters of 
target lesions as a reference
    SD Any case that does not qualify for either PR or PD Any case that does not qualify for either PR or PD
    PD An increase of at least 20% in the sum of the diam-
eters of target lesions, taking the smallest sum of the 
diameters of target lesions recorded since treatment 
started as a reference
An increase of at least 20% in the sum of the diam-
eters of viable (enhancing) target lesions, taking the 
smallest sum of the diameters of viable (enhancing) 
target lesions recorded since treatment started as a 
reference
Nontarget lesions response
    CR Disappearance of all nontarget lesions Disappearance of any intratumor arterial enhancement 
in all nontarget lesions
    IR/SD Persistence of one or more nontarget lesions Persistence of intratumor arterial enhancement in one 
or more nontarget lesions
    PD Appearance of one or more new lesions and/or un-
equivocal progression of existing nontarget lesions
Appearance of one or more new lesions and/or un-
equivocal progression of existing nontarget lesions
mRECIST recommendations
Pleural effusion and ascites Cytopathologic confirmation of the neoplastic nature of any effusion that appears or worsens during treatment is 
required to declare PD
Porta hepatis lymph node Lymph nodes detected at the portal hepatitis can be considered malignant if the lymph node short axis is at least 
2 cm
Portal vein invasion Malignant portal vein invasion should be considered a nonmeasurable lesion and thus included in the nontarget 
lesion group
New lesion A new lesion can be classified as HCC if its longest diameter is at least 1 cm and the enhancement pattern is typi-
cal of HCC. A lesion with an atypical radiological pattern can be diagnosed as HCC by evidence of at least 1-cm 
interval growth
Overall response assessment in mRECIST
Target lesion Nontarget lesion New lesion Overall response
CR CR No CR
CR IR/SD No PR
PR Non-PD No PR
SD Non-PD No SD
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST; CR, complete response; PR, partial response; SD, stable dis-
ease; PD, progressive disease; IR, incomplete response; HCC, hepatocellular carcinoma.
*Adapted from J Hepatol 2012;56:908-94358 and Semin Liver Dis 2010;30:52-60.498
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multicenter study from Korea reports that the recurrence-free 
survival was significantly lower in living donor than DDLT.511 
Thus, follow-up after LDLT should be emphasized, especially in 
countries where most liver transplants are cases are from living 
donors, such as Korea.
Local recurrence rates up to 2 years after treatment are higher 
after RFA (2%–18%) or PEIT (11%–45%) than after surgery, re-
spectively.249-251,259,260 The 4-year cumulative recurrence rate after 
RFA for single tumors <3 cm is 57%. Meanwhile, the 3-/5-year 
cumulative recurrence rates after RFA or PEIT for ≤3 tumors <3 
cm in diameter are 57%/72% and 64%/77%, respectively.512,513 
Incomplete tumor necrosis often occurs after PEIT, and the local 
recurrence rate is up to 43% for large tumors >3 cm.514 RFA for 
patients with a single nodular tumor <2 cm results in a 5-year 
survival rate of 70%.247 Improved survival is anticipated when 
complete response after retreatment with RFA is achieved for 
local recurrence after RFA. Thus, early detection of local recur-
rence after RFA is of the utmost importance.515 
Recurrence usually develops within 2 years after potentially 
curative treatments. Because early detection of recurrence allows 
the possibility of reapplication of curative treatment modali-
ties, posttreatment monitoring should be performed frequently 
enough to detect recurrence as early as possible. However, the 
ideal monitoring intervals and methods require further research. 
Therefore, we recommend follow-up with dynamic enhanced 
imaging (i.e., CT or MRI) or MRI with liver-specific contrast 
agent every 2–6 months for the first 2 years after curative 
treatment. After 2 years without recurrence, follow-up can be 
performed at less frequent intervals. In addition, the monitoring 
interval should be individualized on the basis of patient-specific 
risk factors according to tumor biology and underlying liver 
diseases.516,517
Recommendations (Table 2)
1. Patients with complete response after treatment should 
be followed up with imaging studies (i.e., dynamic contrast-
enhanced CT/MRI or MRI with liver-specific contrast agents) 
and serum tumor markers every 2–6 months in the first 2 years; 
thereafter, patients should be followed by regular checkups at 
individualized intervals (B1).
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Appendix 3. List of Clinical Questions
Internal medicine
    1. Could the incidence of HCC be reduced by primary, secondary, or tertiary prevention?
    2. How should we determine the high-risk group, imaging tests, roles of tumor markers, and diagnostic criteria?
    3. Should we limit exposure to radiation to that necessary to diagnose and treat patients with HCC?
    4. What staging system is applicable in Korea?
    5. Who can obtain a survival benefit from sorafenib therapy? Is it safe and feasible in patients with hepatic impairment?
    6. Does cytotoxic chemotherapy have a role in advanced HCC? Who should be considered for cytotoxic chemotherapy?
    7. Does adjuvant therapy have a role after curative treatment for HCC?
    8. When can preemptive antiviral therapy for hepatitis B be considered for patients undergoing treatment for HCC?
    9. Can preemptive antiviral therapy for hepatitis C be considered for patients undergoing treatment for HCC?
  10. How should we address pain management for patients with HCC?
  11. For what kinds of pain medication should we adjust the dose and intervals? What can we adopt as a parameter of liver function in patients 
with HCC?
  12. What criteria can we use to assess response to HCC treatment?
  13. When and how should we follow-up patients after curative treatment for HCC?
Surgery
    1. Should we consider size of the tumor and patient age when performing liver resection for HCC?
    2. Is it applicable to perform the ICG-R15 test, Fibroscan, MRI, or PET to decide on liver resection?
    3. How good are the outcomes of liver resection in patients with mild portal hypertension?
    4. What is the safe volume of residual liver after liver resection in patients with liver cirrhosis?
    5. Is anatomical resection superior to nonanatomical resection?
    6. Is it useful to perform preconditioning when performing surgical resection for HCC?
    7. Is it useful to perform surgical resection for HCC with bile duct invasion?
    8. Is it useful to perform surgical resection for HCC with vascular invasion?
    9. Is it useful to perform surgical resection for ruptured HCC?
  10. What are the results (i.e., 5-year survival rate, mortality rate, and recurrence rate) of liver resection?
  11. Is laparoscopic liver resection comparable to open resection? What are the advantages and indications?
  12. When can we recommend liver transplantation as a primary treatment?
  13. Do subcentimeter nodules alter the indications for liver transplantation?
  14. What tests should be performed to investigate extrahepatic spread prior to liver transplantation?
  15. How can we manage patients with HCC on the waiting list for liver transplantation? Is neoadjuvant therapy effective for them? Does neo-
adjuvant therapy decrease the withdrawal rate?
  16. Can living donor liver transplantation be a substitute for deceased donor liver transplantation?
  17. Do the Milan criteria have a role as indications for living donor liver transplantation or salvage transplantation?
  18. Is the donor safe when performing living donor liver transplantation?
  19. Can salvage transplantation be curative for recurred HCC?
  20. Is it safe to perform salvage transplantation for recurred HCC after surgical resection?
  21. What kinds of bridging therapies are available for patients on the transplant waiting list? Do they have a clinical impact?
  22. When do we need to downstage HCC prior to liver transplantation? Can we improve clinical outcomes or broaden indications?
  23. How should we treat liver transplant recipients with immunosuppressive or antiviral agents?
  24. Should patients receive adjuvant therapy after liver transplantation? Is it useful or necessary?
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Appendix 3. Continued
Radiology
    1. Is it applicable to diagnose HCC on the basis of noninvasive criteria using 4-phase multidetector CT or liver dynamic contrast-enhanced 
MRI? Should this only be done for patients with liver cirrhosis?
    2. What is the size limit for a lesion for non-invasive diagnostic criteria?
    3. What is the accuracy of noninvasive diagnostic criteria for a subcentimeter lesion with typical enhancement?
    4. Can we use dynamic Gd-EOB-DTPA contrast-enhanced MRI as a surveillance test? Can it be allowed as a first-line test for a lesion identi-
fied by ultrasonography?
    5. Can low signal intensity on the hepatobiliary phase of dynamic Gd-EOB-DTPA contrast-enhanced MRI be accepted as a parameter for 
noninvasive diagnostic criteria?
    6. Should T2-weighted or diffusion-weighted imaging be included as a parameter for noninvasive diagnostic criteria?
    7. Is contrast-enhanced ultrasound acceptable as a method for noninvasive diagnostic criteria?
    8. How long should be the intervals between follow-up CT for patients with HCC?
    9. Is radiofrequency ablation comparable with surgical resection for HCC with respect to survival?
  10. When does combination therapy of radiofrequency ablation and transarterial chemoembolization have advantage over radiofrequency 
ablation monotherapy?
  11. Are patients treated with radiofrequency ablation more likely to have microscopically residual disease (R1) than those treated with surgical 
resection?
  12. Does local recurrence affect long-term survival after locoregional therapy?
  13. How can the technical limitations of radiofrequency ablation due to location or invisibility of lesions be overcome?
  14. Is percutaneous ethanol injection safer than radiofrequency ablation for HCC adjacent to the central bile duct?
  15. Does radiofrequency ablation have a role for recurred HCC following surgical resection?
  16. Do newer methods of locoregional therapy such as cryoablation or microwave ablation have a role?
  17. When can we recommend transarterial chemoembolization as a first-line treatment?
  18. Can we recommend transarterial chemoembolization as a curative therapy for HCCs that are curable but not amenable to other curative 
treatments?
  19. Can we recommend transarterial chemoembolization for advanced HCCs with vascular invasion or metastasis?
  20. Is there a role of chemolipiodolization?
  21. Is there a role of combination therapy of transarterial chemoembolization and other therapies such as radiofrequency ablation, percutane-
ous ethanol injection, radiotherapy, and sorafenib?
  22. When can we recommend drug-eluting bead transarterial chemoembolization? Does it have any advantage over conventional transarterial 
chemoembolization, or can we recommend it as a standard therapy?
  23. Is transarterial radioembolization safe? When can we recommend transarterial radioembolization? Does transarterial radioembolization 
gain any advantage or survival benefit over conventional transarterial chemoembolization? Is it useful for downstaging prior to liver trans-
plantation? Can we recommend it as a standard therapy?
Radio-oncology
    1. When can external-beam radiotherapy be performed? What are the indications for external-beam radiotherapy?
    2. Does combined radiotherapy play a role in the treatment of localized HCCs where transarterial chemoembolization is not expected to be 
effective?
    3. Can we recommend external-beam radiotherapy for HCC with portal vein tumor thrombosis?
    4. Can we recommend external-beam radiotherapy for HCCs <5 cm not amenable to surgical resection or locoregional therapy?
    5. Can we recommend external-beam radiotherapy to alleviate pain or symptoms caused by distant metastases?
    6. Can external-beam radiotherapy play a role in bridging therapy in advanced HCCs prior to surgical resection? 
    7. Can we treat advanced HCCs with a combination of external-beam radiotherapy and systemic chemotherapy? 
HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; PET, positron emission tomography; CT, computed tomography; Gd-EOB-
DTPA, gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid.
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Appendix 4. Process of the Revision of 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma
2003 July: Release of 2003 KLCSG-NCC Korea practice guideline for the management of HCC
2009 June: Release of 2009 KLCSG-NCC Korea practice guideline for the management of HCC
2013 June: The KLCSG Chairman (SW Paik) suggested revision of KLCSG-NCC Korea guidelines
2014 September: Funding from National Cancer Center, Korea for the 2014 HCC practice guideline revision (grant #1311250, P.I. JW Park)
2014 October: The KLCSG and NCC Korea approved the 2014 KLCSG-NCC Korea HCC Practice Guideline Revision Committee (PGRC)
2013 October: Opening and workshop of the HCC PGRC at Seoul National University Hospital
2013 November–2014 April: general meetings and communications between subcommittees
2014 April: Advisory board meeting 
Advisory board members: Byung Ihn Choi (Seoul National University), Byung Chul Yoo (Sungkyunkwan University), Cheol Keun Park 
(Sungkyunkwan University), Kwang Hyub Han (Yonsei University), Hee Jung Wang (Ajou University), Yun Hwan Kim (Korea Univer-
sity), Kwan Sik Lee (Yonsei University), Seung Woon Paik (Sungkyunkwan University)
2014 May: Public hearing at Clinical Research Institution Auditorium, Seoul National University Hospital
2014 June: Both the KLCSG board of directors and NCC, Korea approved the final manuscript of HCC guidelines
2014 June 14: Release of 2014 KLCSG-NCC Korea Practice Guideline for the Management of HCC at the general meeting of KLCSG annual con-
ference, Jeju province
KLCSG, Korean Liver Cancer Study Group; NCC, National Cancer Center; HCC, hepatocellular carcinoma.
Appendix 5. Liver Dynamic Contrast-Enhanced MRI Requirements for the Assessment of Hepatocellular Carcinoma 
Characteristic Specification Comment
MRI equipment ≥1.5 T
Contrast agent Gadolinium-based agents or hepatobiliary-specific 
agents (gadolinium ethoxybenzyl diethylenetri-
amine pentaacetic acid)
Necessary to inject the manufacturer’s sug-
gested dose of contrast agent at a rapid rate of 
1–3 mL/sec
Required imaging technique 1. T2-weighted image
2. In/opposed phase T1-weighted image
3. Diffusion-weighted image
4. Fat-suppressed three-dimensional T1-weighted 
image before and after contrast administration
Necessary for the patient to hold their breath 
for approximately 20 sec for optimal dynamic 
MRI
Dynamic phases and timing required for 
  dynamic contrast-enhanced MRI
1. Late arterial phase
2. Portal venous phase 
3. Delayed or transitional* phase 
1. 5 sec after maximum aortic enhancement 
2. 1 min after contrast injection (35–55 sec 
after the arterial phase)
3. 2–3 min after contrast injection (optimal 
timing is 3 min)
* It is called the transitional phase because it is 
enhanced by hepatocyte-specific uptake for 
hepatobiliary-specific contrast agents. 
Hepatobiliary-specific contrast agent is help-
ful for detecting small HCCs because it has a 
hepatobiliary phase 10–40 min after contrast 
injection and the liver parenchyma shows 
strong enhancement by hepatocyte-specific 
uptake 
Slice thickness and resolution Thickness: <5 to ~8 mm
Resolution: <3 mm
MRI, magnetic resonance imaging; HCC, hepatocellular carcinoma.
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Appendix 6. Liver Dynamic Contrast-Enhanced Computed Tomography Requirements for the Assessment of Hepatocellular Carcinoma
Characteristic Specification Comment
CT imaging equipment Multidetector CT scanner with ≥4 detectors
Contrast agents Contrast agents at a concentration of ≥300 mgI/mL Necessary to rapidly inject contrast agent at a dose of 
  520–600 mgI/kg at 2–5 mL/sec 
Dynamic phases and timing 
  required for dynamic 
  contrast-enhanced CT
1. Late arterial phase
2. Portal venous phase 
3. Delayed phase 
1. 15–20 sec after maximum aortic enhancement 
2. 60–80 sec after contrast injection
3. 2–3 min after contrast injection (optimal timing is 3 min) 
Slice thickness/reconstruction 
  interval 
Thickness: 5 mm
Interval: 50%–100% of thickness
CT, computed tomography.
